6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
discussed	VBN	discussed	discussed	discuss	N	O
in	IN	in	in	in	N	O
greater	JJR	greater	greater	greater	N	O
detail	NN	detail	detail	detail	N	O
in	IN	in	in	in	N	O
another	DT	another	another	anoth	N	O
section	NN	section	section	section	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
label	NN	label	label	label	N	O
:	:	:	:	:	N	O

New	NNP	new	new	new	N	O
Primary	NNP	primary	primary	primari	N	B-AdverseReaction
Malignancies	NNP	malignancies	malignancy	malign	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)]	NN	)]	)]	)]	N	O

Tumor	NN	tumor	tumor	tumor	N	B-AdverseReaction
Promotion	NNP	promotion	promotion	promot	Y	I-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
BRAF	NNP	braf	braf	braf	N	I-AdverseReaction
Wild	NNP	wild	wild	wild	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
Type	NN	type	type	type	N	I-AdverseReaction
Melanoma	NNP	melanoma	melanoma	melanoma	Y	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)]	NN	)]	)]	)]	N	O

Hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	B-AdverseReaction
[	VBD	[	[	[	N	O
see	JJ	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)]	NN	)]	)]	)]	N	O

Venous	JJ	venous	venous	venou	N	B-AdverseReaction
Thromboembolism	NNP	thromboembolism	thromboembolism	thromboembol	Y	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)]	NN	)]	)]	)]	N	O

Cardiomyopathy	JJ	cardiomyopathy	cardiomyopathy	cardiomyopathi	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)]	NN	)]	)]	)]	N	O

Ocular	JJ	ocular	ocular	ocular	N	B-AdverseReaction
Toxicities	NNS	toxicities	toxicity	toxic	N	I-AdverseReaction
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)]	NN	)]	)]	)]	N	O

Serious	JJ	serious	serious	seriou	N	B-Severity
Febrile	NNP	febrile	febrile	febril	N	B-AdverseReaction
Reactions	NNP	reactions	reaction	reaction	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.7	CD	5.7	5.7	5.7	N	O
)]	NN	)]	)]	)]	N	O

Serious	JJ	serious	serious	seriou	N	B-Severity
Skin	NNP	skin	skin	skin	N	B-AdverseReaction
Toxicity	NNP	toxicity	toxicity	toxic	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.8	CD	5.8	5.8	5.8	N	O
)]	NN	)]	)]	)]	N	O

Hyperglycemia	NNP	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.9	CD	5.9	5.9	5.9	N	O
)]	NN	)]	)]	)]	N	O

Glucose	NNP	glucose	glucose	glucos	Y	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
6	CD	6	6	6	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
Phosphate	NN	phosphate	phosphate	phosphat	Y	I-AdverseReaction
Dehydrogenase	NNP	dehydrogenase	dehydrogenase	dehydrogenas	N	I-AdverseReaction
Deficiency	NNP	deficiency	deficiency	defici	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.10	CD	5.10	5.10	5.10	N	O
)]	NN	)]	)]	)]	N	O

Most	JJS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
20%	CD	20%	20%	20%	N	O
)	)	)	)	)	N	O
for	IN	for	for	for	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
single	JJ	single	single	singl	N	O
agent	NN	agent	agent	agent	N	O
are	VBP	are	are	are	N	O
hyperkeratosis	NN	hyperkeratosis	hyperkeratosis	hyperkeratosi	Y	B-AdverseReaction
,	,	,	,	,	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
,	,	,	,	,	N	O
pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
,	,	,	,	,	N	O
arthralgia	NN	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
,	,	,	,	,	N	O
papilloma	NN	papilloma	papilloma	papilloma	Y	B-AdverseReaction
,	,	,	,	,	N	O
alopecia	NN	alopecia	alopecia	alopecia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
palmar	SYM	palmar	palmar	palmar	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
plantar	NN	plantar	plantar	plantar	N	I-AdverseReaction
erythrodysesthesia	JJ	erythrodysesthesia	erythrodysesthesia	erythrodysesthesia	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O

Most	JJS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
20%	CD	20%	20%	20%	N	O
)	)	)	)	)	N	O
for	IN	for	for	for	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NNS	trametinib	trametinib	trametinib	N	O
are	VBP	are	are	are	N	O
pyrexia	JJ	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
,	,	,	,	,	N	O
chills	NNS	chills	chill	chill	Y	B-AdverseReaction
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
,	,	,	,	,	N	O
cough	NN	cough	cough	cough	Y	B-AdverseReaction
,	,	,	,	,	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
,	,	,	,	,	N	O
arthralgia	NN	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
,	,	,	,	,	N	O
night	NN	night	night	night	N	B-AdverseReaction
sweats	NNS	sweats	sweat	sweat	N	I-AdverseReaction
,	,	,	,	,	N	O
decreased	VBD	decreased	decreased	decreas	N	B-AdverseReaction
appetite	RB	appetite	appetite	appetit	N	I-AdverseReaction
,	,	,	,	,	N	O
constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
myalgia	NN	myalgia	myalgia	myalgia	Y	B-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
To	TO	to	to	to	N	O
report	VB	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
GlaxoSmithKline	NNP	glaxosmithkline	glaxosmithkline	glaxosmithklin	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
888	CD	888	888	888	N	O
-	:	-	-	-	N	O
825	CD	825	825	825	N	O
-	:	-	-	-	N	O
5249	CD	5249	5249	5249	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	JJ	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O
.	.	.	.	.	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O

Trials	NNS	trials	trial	trial	N	O
Experience	NN	experience	experience	experi	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
data	NN	data	data	data	N	O
described	NN	described	described	describ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
section	NN	section	section	section	N	O
and	CC	and	and	and	N	O
below	IN	below	below	below	N	O
reflect	JJ	reflect	reflect	reflect	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
single	JJ	single	single	singl	N	O
agent	NN	agent	agent	agent	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
.	.	.	.	.	N	O

BRAF	NNP	braf	braf	braf	N	O
V600E	NNP	v600e	v600e	v600e	N	O
Unresectable	NNP	unresectable	unresectable	unresect	N	O
or	CC	or	or	or	N	O
Metastatic	JJ	metastatic	metastatic	metastat	N	O
Melanoma	NN	melanoma	melanoma	melanoma	Y	O
:	:	:	:	:	N	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
of	IN	of	of	of	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
single	JJ	single	single	singl	N	O
agent	NN	agent	agent	agent	N	O
was	VBD	was	wa	wa	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
in	IN	in	in	in	N	O
586	CD	586	586	586	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
BRAF	NNP	braf	braf	braf	N	O
V600	NNP	v600	v600	v600	N	O
mutation	NN	mutation	mutation	mutat	N	O
-	:	-	-	-	N	O
positive	JJ	positive	positive	posit	N	O
unresectable	JJ	unresectable	unresectable	unresect	N	O
or	CC	or	or	or	N	O
metastatic	JJ	metastatic	metastatic	metastat	N	O
melanoma	NN	melanoma	melanoma	melanoma	Y	O
,	,	,	,	,	N	O
previously	RB	previously	previously	previous	N	O
treated	VBD	treated	treated	treat	N	O
or	CC	or	or	or	N	O
untreated	JJ	untreated	untreated	untreat	N	O
,	,	,	,	,	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
150	CD	150	150	150	N	O
mg	NN	mg	mg	mg	N	O
orally	RB	orally	orally	oral	N	O
twice	JJ	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
until	IN	until	until	until	N	O
disease	JJ	disease	disease	diseas	N	O
progression	NN	progression	progression	progress	N	O
or	CC	or	or	or	N	O
unacceptable	JJ	unacceptable	unacceptable	unaccept	N	O
toxicity	NN	toxicity	toxicity	toxic	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
181	CD	181	181	181	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
for	IN	for	for	for	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
6	CD	6	6	6	N	O
months	NNS	months	month	month	N	O
and	CC	and	and	and	N	O
86	CD	86	86	86	N	O
additional	JJ	additional	additional	addit	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBD	treated	treated	treat	N	O
for	IN	for	for	for	N	O
more	JJR	more	more	more	N	O
than	IN	than	than	than	N	O
12	CD	12	12	12	N	O
months	NNS	months	month	month	N	O
.	.	.	.	.	N	O

TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
was	VBD	was	wa	wa	N	O
studied	VBN	studied	studied	studi	N	O
in	IN	in	in	in	N	O
open	JJ	open	open	open	N	O
-	:	-	-	-	N	O
label	NN	label	label	label	N	O
,	,	,	,	,	N	O
single	JJ	single	single	singl	N	O
-	:	-	-	-	N	O
arm	NN	arm	arm	arm	N	O
trials	NNS	trials	trial	trial	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
an	DT	an	an	an	N	O
open	JJ	open	open	open	N	O
-	:	-	-	-	N	O
label	NN	label	label	label	N	O
,	,	,	,	,	N	O
randomized	VBN	randomized	randomized	random	N	O
,	,	,	,	,	N	O
active	JJ	active	active	activ	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trial	NN	trial	trial	trial	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
daily	JJ	daily	daily	daili	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
was	VBD	was	wa	wa	N	O
300	CD	300	300	300	N	O
mg	NN	mg	mg	mg	N	O
(	(	(	(	(	N	O
range	NN	range	range	rang	N	O
:	:	:	:	:	N	O
118	CD	118	118	118	N	O
to	TO	to	to	to	N	O
300	CD	300	300	300	N	O
mg	NN	mg	mg	mg	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
3	CD	3	3	3	N	O
and	CC	and	and	and	N	O
Table	JJ	table	table	tabl	N	O
4	CD	4	4	4	N	O
present	JJ	present	present	present	N	O
adverse	JJ	adverse	adverse	advers	N	O
drug	NN	drug	drug	drug	N	O
reactions	NNS	reactions	reaction	reaction	N	O
and	CC	and	and	and	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
identified	VBN	identified	identified	identifi	N	O
from	IN	from	from	from	N	O
analyses	NNS	analyses	analysis	analys	N	O
of	IN	of	of	of	N	O
Trial	NNP	trial	trial	trial	N	O
1	CD	1	1	1	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14.1	CD	14.1	14.1	14.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Trial	JJ	trial	trial	trial	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
multicenter	NN	multicenter	multicenter	multicent	N	O
,	,	,	,	,	N	O
international	JJ	international	international	intern	N	O
,	,	,	,	,	N	O
open	JJ	open	open	open	N	O
-	:	-	-	-	N	O
label	NN	label	label	label	N	O
,	,	,	,	,	N	O
randomized	VBN	randomized	randomized	random	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
:	:	:	:	:	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
controlled	VBN	controlled	controlled	control	N	O
trial	NN	trial	trial	trial	N	O
allocated	VBD	allocated	allocated	alloc	N	O
250	CD	250	250	250	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
unresectable	JJ	unresectable	unresectable	unresect	N	O
or	CC	or	or	or	N	O
metastatic	JJ	metastatic	metastatic	metastat	N	O
BRAF	NNP	braf	braf	braf	N	O
V600E	NNP	v600e	v600e	v600e	N	O
mutation	NN	mutation	mutation	mutat	N	O
-	:	-	-	-	N	O
positive	JJ	positive	positive	posit	N	O
melanoma	NN	melanoma	melanoma	melanoma	Y	O
to	TO	to	to	to	N	O
receive	VB	receive	receive	receiv	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
150	CD	150	150	150	N	O
mg	NN	mg	mg	mg	N	O
orally	RB	orally	orally	oral	N	O
twice	JJ	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
187	CD	187	187	187	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
dacarbazine	JJ	dacarbazine	dacarbazine	dacarbazin	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
000	CD	000	000	000	N	O
mg	NN	mg	mg	mg	N	O
m	NN	m	m	m	N	O
2	CD	2	2	2	N	O
intravenously	RB	intravenously	intravenously	intraven	N	O
every	DT	every	every	everi	N	O
3	CD	3	3	3	N	O
weeks	NNS	weeks	week	week	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
63	CD	63	63	63	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
trial	NN	trial	trial	trial	N	O
excluded	VBD	excluded	excluded	exclud	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
abnormal	JJ	abnormal	abnormal	abnorm	N	O
left	VBD	left	left	left	N	O
ventricular	JJ	ventricular	ventricular	ventricular	N	O
ejection	NN	ejection	ejection	eject	N	O
fraction	NN	fraction	fraction	fraction	N	O
or	CC	or	or	or	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	O
valve	NN	valve	valve	valv	N	O
morphology	NN	morphology	morphology	morpholog	N	O
(	(	(	(	(	N	O
Grade	NNP	grade	grade	grade	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
corrected	VBN	corrected	corrected	correct	N	O
QT	NNP	qt	qt	qt	N	O
interval	JJ	interval	interval	interv	N	O
480	CD	480	480	480	N	O
milliseconds	NNS	milliseconds	millisecond	millisecond	N	O
on	IN	on	on	on	N	O
electrocardiogram	NN	electrocardiogram	electrocardiogram	electrocardiogram	Y	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
a	DT	a	a	a	N	O
known	JJ	known	known	known	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
glucose	JJ	glucose	glucose	glucos	Y	O
-	:	-	-	-	N	O
6	CD	6	6	6	N	O
-	:	-	-	-	N	O
phosphate	NN	phosphate	phosphate	phosphat	Y	O
dehydrogenase	NN	dehydrogenase	dehydrogenase	dehydrogenas	N	O
deficiency	NN	deficiency	deficiency	defici	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
duration	NN	duration	duration	durat	N	O
on	IN	on	on	on	N	O
treatment	NN	treatment	treatment	treatment	N	O
was	VBD	was	wa	wa	N	O
4.9	CD	4.9	4.9	4.9	N	O
months	NNS	months	month	month	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
and	CC	and	and	and	N	O
2.8	CD	2.8	2.8	2.8	N	O
months	NNS	months	month	month	N	O
for	IN	for	for	for	N	O
dacarbazine	JJ	dacarbazine	dacarbazine	dacarbazin	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
population	NN	population	population	popul	N	O
exposed	VBD	exposed	exposed	expos	N	O
to	TO	to	to	to	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
was	VBD	was	wa	wa	N	O
60%	CD	60%	60%	60%	N	O
male	NN	male	male	male	N	O
,	,	,	,	,	N	O
99%	CD	99%	99%	99%	N	O
white	JJ	white	white	white	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
median	JJ	median	median	median	N	O
age	NN	age	age	age	N	O
of	IN	of	of	of	N	O
53	CD	53	53	53	N	O
years	NNS	years	year	year	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
commonly	JJ	commonly	commonly	commonli	N	O
occurring	VBG	occurring	occurring	occur	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
20%	CD	20%	20%	20%	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
were	VBD	were	were	were	N	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
order	NN	order	order	order	N	O
of	IN	of	of	of	N	O
decreasing	VBG	decreasing	decreasing	decreas	N	O
frequency	NN	frequency	frequency	frequenc	N	O
:	:	:	:	:	N	O
hyperkeratosis	NN	hyperkeratosis	hyperkeratosis	hyperkeratosi	Y	B-AdverseReaction
,	,	,	,	,	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
,	,	,	,	,	N	O
pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
,	,	,	,	,	N	O
arthralgia	NN	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
,	,	,	,	,	N	O
papilloma	NN	papilloma	papilloma	papilloma	Y	B-AdverseReaction
,	,	,	,	,	N	O
alopecia	NN	alopecia	alopecia	alopecia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
palmar	SYM	palmar	palmar	palmar	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
plantar	NN	plantar	plantar	plantar	N	I-AdverseReaction
erythrodysesthesia	JJ	erythrodysesthesia	erythrodysesthesia	erythrodysesthesia	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
(	(	(	(	(	N	O
PPES	NNP	ppes	ppes	ppe	N	B-AdverseReaction
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
resulting	VBG	resulting	resulting	result	N	O
in	IN	in	in	in	N	O
permanent	JJ	permanent	permanent	perman	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
study	NN	study	study	studi	N	O
medication	NN	medication	medication	medic	N	O
in	IN	in	in	in	N	O
Trial	NNP	trial	trial	trial	N	O
1	CD	1	1	1	N	O
was	VBD	was	wa	wa	N	O
3%	CD	3%	3%	3%	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
and	CC	and	and	and	N	O
3%	CD	3%	3%	3%	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
dacarbazine	NN	dacarbazine	dacarbazine	dacarbazin	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
frequent	JJ	frequent	frequent	frequent	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
adverse	NN	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
dose	VB	dose	dose	dose	N	O
reduction	NN	reduction	reduction	reduct	N	O
of	IN	of	of	of	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
were	VBD	were	were	were	N	O
pyrexia	NNS	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
(	(	(	(	(	N	O
9%	CD	9%	9%	9%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
PPES	NNP	ppes	ppes	ppe	N	B-AdverseReaction
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
chills	NNS	chills	chill	chill	Y	B-AdverseReaction
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
3	CD	3	3	3	N	O
.	.	.	.	.	N	O

Selected	VBN	selected	selected	select	N	O
Common	NNP	common	common	common	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
Occurring	NNP	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
10%	CD	10%	10%	10%	N	O
(	(	(	(	(	N	O
All	NNP	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
2%	CD	2%	2%	2%	N	O
(	(	(	(	(	N	O
Grades	NNP	grades	grade	grade	N	O
3	CD	3	3	3	N	O
or	CC	or	or	or	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
Patients	NNS	patients	patient	patient	N	O
Treated	VBN	treated	treated	treat	N	O
With	IN	with	with	with	N	O
TAFINLARa	NNP	tafinlara	tafinlara	tafinlara	N	O

TAFINLARN	$	tafinlarn	tafinlarn	tafinlarn	N	O
187	CD	187	187	187	N	O
Dacarbazine	NNP	dacarbazine	dacarbazine	dacarbazin	N	O
N	NNP	n	n	n	N	O
59	CD	59	59	59	N	O

Primary	JJ	primary	primary	primari	N	O
System	NNP	system	system	system	N	O
Organ	NNP	organ	organ	organ	N	O
Class	NNP	class	class	class	N	O
Preferred	NNP	preferred	preferred	prefer	N	O
Term	NNP	term	term	term	N	O
All	NNP	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Grades	VBZ	grades	grade	grade	N	O
3	CD	3	3	3	N	O
and	CC	and	and	and	N	O
4	CD	4	4	4	N	O
b	NN	b	b	b	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
All	DT	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Grades	VBZ	grades	grade	grade	N	O
3	CD	3	3	3	N	O
and	CC	and	and	and	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O

Hyperkeratosis	NN	hyperkeratosis	hyperkeratosis	hyperkeratosi	Y	B-AdverseReaction

37	CD	37	37	37	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Alopecia	NN	alopecia	alopecia	alopecia	Y	B-AdverseReaction

22	CD	22	22	22	N	O
NAf	NNP	naf	naf	naf	N	O
2	CD	2	2	2	N	O
NAf	NNP	naf	naf	naf	N	O

Palmar	NNP	palmar	palmar	palmar	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
plantar	NN	plantar	plantar	plantar	N	I-AdverseReaction
erythrodysesthesia	VBZ	erythrodysesthesia	erythrodysesthesia	erythrodysesthesia	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction

20	CD	20	20	20	N	O
2	CD	2	2	2	N	O
2	CD	2	2	2	N	O
0	CD	0	0	0	N	O

Rash	NN	rash	rash	rash	Y	B-AdverseReaction

17	CD	17	17	17	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Nervous	JJ	nervous	nervous	nervou	Y	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O

Headache	NN	headache	headache	headach	Y	B-AdverseReaction

32	CD	32	32	32	N	O
0	CD	0	0	0	N	O
8	CD	8	8	8	N	O
0	CD	0	0	0	N	O

General	NNP	general	general	gener	N	O
disorders	NNS	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
administration	NN	administration	administration	administr	N	O
site	NN	site	site	site	N	O
conditions	NNS	conditions	condition	condit	N	O

Pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction

28	CD	28	28	28	N	O
3	CD	3	3	3	N	O
10	CD	10	10	10	N	O
0	CD	0	0	0	N	O

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	O
and	CC	and	and	and	N	O
connective	JJ	connective	connective	connect	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O

Arthralgia	NN	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction

27	CD	27	27	27	N	O
1	CD	1	1	1	N	O
2	CD	2	2	2	N	O
0	CD	0	0	0	N	O

Back	RB	back	back	back	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction

12	CD	12	12	12	N	O
3	CD	3	3	3	N	O
7	CD	7	7	7	N	O
0	CD	0	0	0	N	O

Myalgia	NN	myalgia	myalgia	myalgia	Y	B-AdverseReaction

11	CD	11	11	11	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Neoplasms	NNP	neoplasms	neoplasm	neoplasm	N	O
benign	NN	benign	benign	benign	N	O
,	,	,	,	,	N	O
malignant	JJ	malignant	malignant	malign	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
unspecified	JJ	unspecified	unspecified	unspecifi	N	O
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
cysts	NNS	cysts	cyst	cyst	N	O
and	CC	and	and	and	N	O
polyps	NNS	polyps	polyp	polyp	Y	O
)	)	)	)	)	N	O

Papilloma	NNP	papilloma	papilloma	papilloma	Y	B-AdverseReaction
c	NN	c	c	c	N	O

27	CD	27	27	27	N	O
0	CD	0	0	0	N	O
2	CD	2	2	2	N	O
0	CD	0	0	0	N	O

cuSCC	NN	cuscc	cuscc	cuscc	N	B-AdverseReaction
d	NN	d	d	d	N	O
,	,	,	,	,	N	O
e	NN	e	e	e	N	O

7	CD	7	7	7	N	O
4	CD	4	4	4	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
thoracic	NN	thoracic	thoracic	thorac	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
mediastinal	JJ	mediastinal	mediastinal	mediastin	N	O
disorders	NNS	disorders	disorder	disord	N	O

Cough	NN	cough	cough	cough	Y	B-AdverseReaction

12	CD	12	12	12	N	O
0	CD	0	0	0	N	O
5	CD	5	5	5	N	O
0	CD	0	0	0	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
disorders	NNS	disorders	disorder	disord	N	O

Constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction

11	CD	11	11	11	N	O
2	CD	2	2	2	N	O
14	CD	14	14	14	N	O
0	CD	0	0	0	N	O

Infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
infestations	NNS	infestations	infestation	infest	N	O

Nasopharyngitis	NN	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction

10	CD	10	10	10	N	O
0	CD	0	0	0	N	O
3	CD	3	3	3	N	O
0	CD	0	0	0	N	O

a	DT	a	a	a	N	O
Adverse	JJ	adverse	adverse	advers	N	O
drug	NN	drug	drug	drug	N	O
reactions	NNS	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
reported	VBD	reported	reported	report	N	O
using	VBG	using	using	use	N	O
MedDRA	NNP	meddra	meddra	meddra	N	O
and	CC	and	and	and	N	O
graded	VBD	graded	graded	grade	N	O
using	VBG	using	using	use	N	O
CTCAE	NNP	ctcae	ctcae	ctcae	N	O
version	NN	version	version	version	N	O
4.0	CD	4.0	4.0	4.0	N	O
for	IN	for	for	for	N	O
assessment	NN	assessment	assessment	assess	N	O
of	IN	of	of	of	N	O
toxicity	NN	toxicity	toxicity	toxic	N	O
.	.	.	.	.	N	O

b	NN	b	b	b	N	O

Grade	$	grade	grade	grade	N	B-Severity
4	CD	4	4	4	N	I-Severity
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
limited	VBD	limited	limited	limit	N	O
to	TO	to	to	to	N	O
hyperkeratosis	NN	hyperkeratosis	hyperkeratosis	hyperkeratosi	Y	B-AdverseReaction
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

c	SYM	c	c	c	N	O
Includes	VBZ	includes	includes	includ	N	O
skin	JJ	skin	skin	skin	N	B-AdverseReaction
papilloma	NN	papilloma	papilloma	papilloma	Y	I-AdverseReaction
and	CC	and	and	and	N	O
papilloma	NN	papilloma	papilloma	papilloma	Y	B-AdverseReaction
.	.	.	.	.	N	O

d	NN	d	d	d	N	O
Includes	NNP	includes	includes	includ	N	O
squamous	JJ	squamous	squamous	squamou	N	B-AdverseReaction
cell	NN	cell	cell	cell	N	I-AdverseReaction
carcinoma	NN	carcinoma	carcinoma	carcinoma	Y	I-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
skin	NN	skin	skin	skin	N	I-AdverseReaction
and	CC	and	and	and	N	O
keratoacanthoma	NN	keratoacanthoma	keratoacanthoma	keratoacanthoma	Y	B-AdverseReaction
.	.	.	.	.	N	O

e	NN	e	e	e	N	O
Cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
cutaneous	JJ	cutaneous	cutaneous	cutan	N	B-AdverseReaction
squamous	JJ	squamous	squamous	squamou	N	I-AdverseReaction
cell	NN	cell	cell	cell	N	I-AdverseReaction
carcinoma	NNS	carcinoma	carcinoma	carcinoma	Y	I-AdverseReaction
were	VBD	were	were	were	N	O
required	VBN	required	required	requir	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
reported	VBN	reported	reported	report	N	O
as	IN	as	a	as	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
per	IN	per	per	per	N	O
protocol	NN	protocol	protocol	protocol	N	O
.	.	.	.	.	N	O

f	NNS	f	f	f	N	O
NA	NNP	na	na	na	N	O
not	RB	not	not	not	N	O
applicable	JJ	applicable	applicable	applic	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
4	CD	4	4	4	N	O
.	.	.	.	.	N	O

Incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
Laboratory	NNP	laboratory	laboratory	laboratori	N	O
Abnormalities	NNP	abnormalities	abnormality	abnorm	N	O
Increased	VBD	increased	increased	increas	N	O
From	NNP	from	from	from	N	O
Baseline	NNP	baseline	baseline	baselin	N	O
Occurring	NNP	occurring	occurring	occur	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
Higher	JJR	higher	higher	higher	N	O
Incidence	NN	incidence	incidence	incid	N	O
in	IN	in	in	in	N	O
Patients	NNS	patients	patient	patient	N	O
Treated	VBN	treated	treated	treat	N	O
With	IN	with	with	with	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
in	IN	in	in	in	N	O
Trial	NNP	trial	trial	trial	N	O
1	CD	1	1	1	N	O
[	NN	[	[	[	N	O
Between	NNP	between	between	between	N	O
-	:	-	-	-	N	O
Arm	NNP	arm	arm	arm	N	O
Difference	NNP	difference	difference	differ	N	O
of	IN	of	of	of	N	O
5%	CD	5%	5%	5%	N	O
(	(	(	(	(	N	O
All	NNP	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
2%	CD	2%	2%	2%	N	O
(	(	(	(	(	N	O
Grades	NNP	grades	grade	grade	N	O
3	CD	3	3	3	N	O
or	CC	or	or	or	N	O
4	CD	4	4	4	N	O
)]	NNS	)]	)]	)]	N	O

Test	NNP	test	test	test	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
N	NNP	n	n	n	N	O
187	CD	187	187	187	N	O
DTIC	NNP	dtic	dtic	dtic	N	O
N	NNP	n	n	n	N	O
59	CD	59	59	59	N	O

All	DT	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Grades	VBZ	grades	grade	grade	N	O
3	CD	3	3	3	N	O
and	CC	and	and	and	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
All	DT	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Grades	VBZ	grades	grade	grade	N	O
3	CD	3	3	3	N	O
and	CC	and	and	and	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

Hyperglycemia	NNP	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction
50	CD	50	50	50	N	O
6	CD	6	6	6	N	O
43	CD	43	43	43	N	O
0	CD	0	0	0	N	O

Hypophosphatemia	NNP	hypophosphatemia	hypophosphatemia	hypophosphatemia	Y	B-AdverseReaction
37	CD	37	37	37	N	O
6	CD	6	6	6	N	O
a	DT	a	a	a	N	O
14	CD	14	14	14	N	O
2	CD	2	2	2	N	O

Increased	VBN	increased	increased	increas	N	B-AdverseReaction
alkaline	JJ	alkaline	alkaline	alkalin	N	I-AdverseReaction
phosphatase	NN	phosphatase	phosphatase	phosphatas	N	I-AdverseReaction
19	CD	19	19	19	N	O
0	CD	0	0	0	N	O
14	CD	14	14	14	N	O
2	CD	2	2	2	N	O

Hyponatremia	NNP	hyponatremia	hyponatremia	hyponatremia	Y	B-AdverseReaction
8	CD	8	8	8	N	O
2	CD	2	2	2	N	O
3	CD	3	3	3	N	O
0	CD	0	0	0	N	O

a	DT	a	a	a	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
4	CD	4	4	4	N	I-Severity
laboratory	NN	laboratory	laboratory	laboratori	N	O
abnormality	NN	abnormality	abnormality	abnorm	N	O
limited	VBD	limited	limited	limit	N	O
to	TO	to	to	to	N	O
hypophosphatemia	VB	hypophosphatemia	hypophosphatemia	hypophosphatemia	Y	B-AdverseReaction
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Other	JJ	other	other	other	N	O

clinically	RB	clinically	clinically	clinic	N	O
important	JJ	important	important	import	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
10%	CD	10%	10%	10%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
586	CD	586	586	586	N	O
)	)	)	)	)	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
were	VBD	were	were	were	N	O
:	:	:	:	:	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	B-AdverseReaction
.	.	.	.	.	N	O

Immune	NNP	immune	immune	immun	N	O
System	NNP	system	system	system	N	O
Disorders	NNPS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
manifesting	NN	manifesting	manifesting	manifest	N	O
as	IN	as	a	as	N	O
bullous	JJ	bullous	bullous	bullou	N	B-AdverseReaction
rash	NN	rash	rash	rash	Y	I-AdverseReaction
.	.	.	.	.	N	O

Renal	NNP	renal	renal	renal	N	O
and	CC	and	and	and	N	O
Urinary	JJ	urinary	urinary	urinari	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Interstitial	JJ	interstitial	interstitial	interstiti	N	B-AdverseReaction
nephritis	NN	nephritis	nephritis	nephriti	Y	I-AdverseReaction
.	.	.	.	.	N	O

BRAF	NNP	braf	braf	braf	N	O
V600E	NNP	v600e	v600e	v600e	N	O
or	CC	or	or	or	N	O
V600K	NNP	v600k	v600k	v600k	N	O
Unresectable	NNP	unresectable	unresectable	unresect	N	O
or	CC	or	or	or	N	O
Metastatic	JJ	metastatic	metastatic	metastat	N	O
Melanoma	NN	melanoma	melanoma	melanoma	Y	O
:	:	:	:	:	N	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
of	IN	of	of	of	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
was	VBD	was	wa	wa	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
in	IN	in	in	in	N	O
Trial	NNP	trial	trial	trial	N	O
2	CD	2	2	2	N	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
trials	NNS	trials	trial	trial	N	O
consisting	VBG	consisting	consisting	consist	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
total	NN	total	total	total	N	O
of	IN	of	of	of	N	O
202	CD	202	202	202	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
BRAF	NNP	braf	braf	braf	N	O
V600	NNP	v600	v600	v600	N	O
mutation	NN	mutation	mutation	mutat	N	O
-	:	-	-	-	N	O
positive	JJ	positive	positive	posit	N	O
unresectable	JJ	unresectable	unresectable	unresect	N	O
or	CC	or	or	or	N	O
metastatic	JJ	metastatic	metastatic	metastat	N	O
melanoma	NN	melanoma	melanoma	melanoma	Y	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
150	CD	150	150	150	N	O
mg	NN	mg	mg	mg	N	O
orally	RB	orally	orally	oral	N	O
twice	JJ	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	JJ	trametinib	trametinib	trametinib	N	O
2	CD	2	2	2	N	O
mg	NN	mg	mg	mg	N	O
orally	RB	orally	orally	oral	N	O
once	RB	once	once	onc	N	O
daily	JJ	daily	daily	daili	N	O
until	IN	until	until	until	N	O
disease	JJ	disease	disease	diseas	N	O
progression	NN	progression	progression	progress	N	O
or	CC	or	or	or	N	O
unacceptable	JJ	unacceptable	unacceptable	unaccept	N	O
toxicity	NN	toxicity	toxicity	toxic	N	O
.	.	.	.	.	N	O

Among	IN	among	among	among	N	O
these	DT	these	these	these	N	O
202	CD	202	202	202	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
66	CD	66	66	66	N	O
(	(	(	(	(	N	O
33%	CD	33%	33%	33%	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
exposed	VBN	exposed	exposed	expos	N	O
to	TO	to	to	to	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
and	CC	and	and	and	N	O
68	CD	68	68	68	N	O
(	(	(	(	(	N	O
34%	CD	34%	34%	34%	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
exposed	VBN	exposed	exposed	expos	N	O
to	TO	to	to	to	N	O
trametinib	VB	trametinib	trametinib	trametinib	N	O
for	IN	for	for	for	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
6	CD	6	6	6	N	O
to	TO	to	to	to	N	O
12	CD	12	12	12	N	O
months	NNS	months	month	month	N	O
while	IN	while	while	while	N	O
40	CD	40	40	40	N	O
(	(	(	(	(	N	O
20%	CD	20%	20%	20%	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
exposed	VBN	exposed	exposed	expos	N	O
to	TO	to	to	to	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
and	CC	and	and	and	N	O
36	CD	36	36	36	N	O
(	(	(	(	(	N	O
18%	CD	18%	18%	18%	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
exposed	VBN	exposed	exposed	expos	N	O
to	TO	to	to	to	N	O
trametinib	VB	trametinib	trametinib	trametinib	N	O
for	IN	for	for	for	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
one	CD	one	one	one	N	O
year	NN	year	year	year	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
age	NN	age	age	age	N	O
was	VBD	was	wa	wa	N	O
54	CD	54	54	54	N	O
years	NNS	years	year	year	N	O
,	,	,	,	,	N	O
57%	CD	57%	57%	57%	N	O
were	VBD	were	were	were	N	O
male	NN	male	male	male	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
99%	CD	99%	99%	99%	N	O
were	VBD	were	were	were	N	O
white	JJ	white	white	white	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
5	CD	5	5	5	N	O
presents	NNS	presents	present	present	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
from	IN	from	from	from	N	O
Trial	JJ	trial	trial	trial	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
multicenter	NN	multicenter	multicenter	multicent	N	O
,	,	,	,	,	N	O
open	JJ	open	open	open	N	O
-	:	-	-	-	N	O
label	NN	label	label	label	N	O
,	,	,	,	,	N	O
randomized	VBN	randomized	randomized	random	N	O
trial	NN	trial	trial	trial	N	O
of	IN	of	of	of	N	O
162	CD	162	162	162	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
BRAF	NNP	braf	braf	braf	N	O
V600E	NNP	v600e	v600e	v600e	N	O
or	CC	or	or	or	N	O
V600K	NNP	v600k	v600k	v600k	N	O
mutation	NN	mutation	mutation	mutat	N	O
-	:	-	-	-	N	O
positive	JJ	positive	positive	posit	N	O
melanoma	NN	melanoma	melanoma	melanoma	Y	O
receiving	VBG	receiving	receiving	receiv	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
150	CD	150	150	150	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	JJ	trametinib	trametinib	trametinib	N	O
2	CD	2	2	2	N	O
mg	NN	mg	mg	mg	N	O
orally	RB	orally	orally	oral	N	O
once	RB	once	once	onc	N	O
daily	JJ	daily	daily	daili	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
55	CD	55	55	55	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
150	CD	150	150	150	N	O
mg	NN	mg	mg	mg	N	O
orally	RB	orally	orally	oral	N	O
twice	JJ	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	JJ	trametinib	trametinib	trametinib	N	O
1	CD	1	1	1	N	O
mg	NN	mg	mg	mg	N	O
once	RB	once	once	onc	N	O
daily	JJ	daily	daily	daili	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
54	CD	54	54	54	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
single	JJ	single	single	singl	N	O
agent	NN	agent	agent	agent	N	O
150	CD	150	150	150	N	O
mg	NN	mg	mg	mg	N	O
orally	RB	orally	orally	oral	N	O
twice	JJ	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
53	CD	53	53	53	N	O
)	)	)	)	)	N	O
[	NN	[	[	[	N	O
see	VBP	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14.2	CD	14.2	14.2	14.2	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
abnormal	JJ	abnormal	abnormal	abnorm	N	O
LVEF	NNP	lvef	lvef	lvef	N	O
,	,	,	,	,	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
acute	JJ	acute	acute	acut	N	O
coronary	JJ	coronary	coronary	coronari	N	O
syndrome	NN	syndrome	syndrome	syndrom	N	O
within	IN	within	within	within	N	O
6	CD	6	6	6	N	O
months	NNS	months	month	month	N	O
,	,	,	,	,	N	O
current	JJ	current	current	current	N	O
evidence	NN	evidence	evidence	evid	N	O
of	IN	of	of	of	N	O
Class	NNP	class	class	class	N	O
II	NNP	ii	ii	ii	N	O
or	CC	or	or	or	N	O
greater	JJR	greater	greater	greater	N	O
congestive	JJ	congestive	congestive	congest	N	O
heart	NN	heart	heart	heart	N	O
failure	NN	failure	failure	failur	N	O
(	(	(	(	(	N	O
New	NNP	new	new	new	N	O
York	NNP	york	york	york	N	O
Heart	NNP	heart	heart	heart	N	O
Association	NNP	association	association	associ	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
history	NN	history	history	histori	N	O
RVO	NNP	rvo	rvo	rvo	N	O
or	CC	or	or	or	N	O
RPED	NNP	rped	rped	rped	N	O
,	,	,	,	,	N	O
QTc	NNP	qtc	qtc	qtc	Y	O
interval	VBZ	interval	interval	interv	N	O
480	CD	480	480	480	N	O
msec	NN	msec	msec	msec	N	O
,	,	,	,	,	N	O
treatment	NN	treatment	treatment	treatment	N	O
refractory	NN	refractory	refractory	refractori	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	O
,	,	,	,	,	N	O
uncontrolled	JJ	uncontrolled	uncontrolled	uncontrol	N	O
arrhythmias	NN	arrhythmias	arrhythmia	arrhythmia	N	O
,	,	,	,	,	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	O
or	CC	or	or	or	N	O
interstitial	JJ	interstitial	interstitial	interstiti	N	O
lung	NN	lung	lung	lung	N	O
disease	NN	disease	disease	diseas	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
a	DT	a	a	a	N	O
known	JJ	known	known	known	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
G6PD	NNP	g6pd	g6pd	g6pd	N	O
deficiency	NN	deficiency	deficiency	defici	N	O
were	VBD	were	were	were	N	O
excluded	VBN	excluded	excluded	exclud	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
was	VBD	was	wa	wa	N	O
10.9	CD	10.9	10.9	10.9	N	O
months	NNS	months	month	month	N	O
for	IN	for	for	for	N	O
both	DT	both	both	both	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
and	CC	and	and	and	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
-	:	-	-	-	N	O
mg	NN	mg	mg	mg	N	O
orally	RB	orally	orally	oral	N	O
once	RB	once	once	onc	N	O
-	:	-	-	-	N	O
daily	JJ	daily	daily	daili	N	O
treatment	NN	treatment	treatment	treatment	N	O
group	NN	group	group	group	N	O
)	)	)	)	)	N	O
when	WRB	when	when	when	N	O
used	VBN	used	used	use	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
,	,	,	,	,	N	O
10.6	CD	10.6	10.6	10.6	N	O
months	NNS	months	month	month	N	O
for	IN	for	for	for	N	O
both	DT	both	both	both	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
and	CC	and	and	and	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
mg	NN	mg	mg	mg	N	O
orally	RB	orally	orally	oral	N	O
once	RB	once	once	onc	N	O
-	:	-	-	-	N	O
daily	JJ	daily	daily	daili	N	O
treatment	NN	treatment	treatment	treatment	N	O
group	NN	group	group	group	N	O
)	)	)	)	)	N	O
when	WRB	when	when	when	N	O
used	VBN	used	used	use	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
6.1	CD	6.1	6.1	6.1	N	O
months	NNS	months	month	month	N	O
for	IN	for	for	for	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
single	JJ	single	single	singl	N	O
agent	NN	agent	agent	agent	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
Trial	NNP	trial	trial	trial	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
13%	CD	13%	13%	13%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
experienced	JJ	experienced	experienced	experienc	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
resulting	VBG	resulting	resulting	result	N	O
in	IN	in	in	in	N	O
permanent	JJ	permanent	permanent	perman	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
trial	NN	trial	trial	trial	N	O
medication	NN	medication	medication	medic	N	O
(	(	(	(	(	N	O
s	NN	s	s	s	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
resulting	VBG	resulting	resulting	result	N	O
in	IN	in	in	in	N	O
permanent	JJ	permanent	permanent	perman	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
was	VBD	was	wa	wa	N	O
pyrexia	VBN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
led	VBD	led	led	led	N	O
to	TO	to	to	to	N	O
dose	VB	dose	dose	dose	N	O
reductions	NNS	reductions	reduction	reduct	N	O
in	IN	in	in	in	N	O
49%	CD	49%	49%	49%	N	O
and	CC	and	and	and	N	O
dose	JJ	dose	dose	dose	N	O
interruptions	NNS	interruptions	interruption	interrupt	N	O
in	IN	in	in	in	N	O
67%	CD	67%	67%	67%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
.	.	.	.	.	N	O

Pyrexia	NNP	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
,	,	,	,	,	N	O
chills	NNS	chills	chill	chill	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
were	VBD	were	were	were	N	O
the	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
reasons	NNS	reasons	reason	reason	N	O
cited	VBD	cited	cited	cite	N	O
for	IN	for	for	for	N	O
dose	NN	dose	dose	dose	N	O
reductions	NNS	reductions	reduction	reduct	N	O
and	CC	and	and	and	N	O
pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
,	,	,	,	,	N	O
chills	NNS	chills	chill	chill	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
decreased	JJ	decreased	decreased	decreas	N	B-AdverseReaction
ejection	NN	ejection	ejection	eject	N	I-AdverseReaction
fraction	NN	fraction	fraction	fraction	N	I-AdverseReaction
were	VBD	were	were	were	N	O
the	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
reasons	NNS	reasons	reason	reason	N	O
cited	VBD	cited	cited	cite	N	O
for	IN	for	for	for	N	O
dose	JJ	dose	dose	dose	N	O
interruptions	NNS	interruptions	interruption	interrupt	N	O
of	IN	of	of	of	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
and	CC	and	and	and	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
when	WRB	when	when	when	N	O
used	VBN	used	used	use	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
5	CD	5	5	5	N	O
.	.	.	.	.	N	O

Common	JJ	common	common	common	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Drug	NNP	drug	drug	drug	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
Occurring	NNP	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
10%	CD	10%	10%	10%	N	O
at	IN	at	at	at	N	O
(	(	(	(	(	N	O
All	NNP	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
5%	CD	5%	5%	5%	N	O
(	(	(	(	(	N	O
Grades	NNP	grades	grade	grade	N	O
3	CD	3	3	3	N	O
or	CC	or	or	or	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
Patients	NNS	patients	patient	patient	N	O
Treated	VBN	treated	treated	treat	N	O
With	IN	with	with	with	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
in	IN	in	in	in	N	O
Combination	NNP	combination	combination	combin	N	O
With	IN	with	with	with	N	O
Trametinib	NNP	trametinib	trametinib	trametinib	N	O
in	IN	in	in	in	N	O
Trial	NNP	trial	trial	trial	N	O
2	CD	2	2	2	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
plus	CC	plus	plus	plu	N	O
Trametinib	NNP	trametinib	trametinib	trametinib	N	O
2	CD	2	2	2	N	O
mg	NN	mg	mg	mg	N	O
N	NNP	n	n	n	N	O
55	CD	55	55	55	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
plus	CC	plus	plus	plu	N	O
Trametinib	NNP	trametinib	trametinib	trametinib	N	O
1	CD	1	1	1	N	O
mg	NN	mg	mg	mg	N	O
N	NNP	n	n	n	N	O
54	CD	54	54	54	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
N	NNP	n	n	n	N	O
53	CD	53	53	53	N	O

All	DT	all	all	all	N	O
Gradesa	NNP	gradesa	gradesa	gradesa	N	O
Grades	NNP	grades	grade	grade	N	O
3	CD	3	3	3	N	O
and	CC	and	and	and	N	O
4	CD	4	4	4	N	O
All	DT	all	all	all	N	O
Gradesa	NNP	gradesa	gradesa	gradesa	N	O
Grades	NNP	grades	grade	grade	N	O
3	CD	3	3	3	N	O
and	CC	and	and	and	N	O
4	CD	4	4	4	N	O
All	DT	all	all	all	N	O
Gradesa	NNP	gradesa	gradesa	gradesa	N	O
Grades	NNP	grades	grade	grade	N	O
3	CD	3	3	3	N	O
and	CC	and	and	and	N	O
4	CD	4	4	4	N	O

General	NNP	general	general	gener	N	O
disorders	NNS	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
administrative	JJ	administrative	administrative	administr	N	O
site	NN	site	site	site	N	O
conditions	NNS	conditions	condition	condit	N	O

Pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction

71	CD	71	71	71	N	O
5	CD	5	5	5	N	O
69	CD	69	69	69	N	O
9	CD	9	9	9	N	O
26	CD	26	26	26	N	O
0	CD	0	0	0	N	O

Chills	NNS	chills	chill	chill	Y	B-AdverseReaction

58	CD	58	58	58	N	O
2	CD	2	2	2	N	O
50	CD	50	50	50	N	O
2	CD	2	2	2	N	O
17	CD	17	17	17	N	O
0	CD	0	0	0	N	O

Fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction

53	CD	53	53	53	N	O
4	CD	4	4	4	N	O
57	CD	57	57	57	N	O
2	CD	2	2	2	N	O
40	CD	40	40	40	N	O
6	CD	6	6	6	N	O

Edema	NNP	edema	edema	edema	Y	B-AdverseReaction
peripheral	NN	peripheral	peripheral	peripher	N	I-AdverseReaction
b	NN	b	b	b	N	O

31	CD	31	31	31	N	O
0	CD	0	0	0	N	O
28	CD	28	28	28	N	O
0	CD	0	0	0	N	O
17	CD	17	17	17	N	O
0	CD	0	0	0	N	O

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O

Rash	NNP	rash	rash	rash	Y	B-AdverseReaction
c	NN	c	c	c	N	O

45	CD	45	45	45	N	O
0	CD	0	0	0	N	O
43	CD	43	43	43	N	O
2	CD	2	2	2	N	O
53	CD	53	53	53	N	O
0	CD	0	0	0	N	O

Night	NNP	night	night	night	N	B-AdverseReaction
Sweats	NNP	sweats	sweat	sweat	N	I-AdverseReaction

24	CD	24	24	24	N	O
0	CD	0	0	0	N	O
15	CD	15	15	15	N	O
0	CD	0	0	0	N	O
6	CD	6	6	6	N	O
0	CD	0	0	0	N	O

Dry	NNP	dry	dry	dri	N	B-AdverseReaction
skin	NN	skin	skin	skin	N	I-AdverseReaction

18	CD	18	18	18	N	O
0	CD	0	0	0	N	O
9	CD	9	9	9	N	O
0	CD	0	0	0	N	O
6	CD	6	6	6	N	O
0	CD	0	0	0	N	O

Dermatitis	NN	dermatitis	dermatitis	dermat	Y	B-AdverseReaction
acneiform	NN	acneiform	acneiform	acneiform	N	I-AdverseReaction

16	CD	16	16	16	N	O
0	CD	0	0	0	N	O
11	CD	11	11	11	N	O
0	CD	0	0	0	N	O
4	CD	4	4	4	N	O
0	CD	0	0	0	N	O

Actinic	JJ	actinic	actinic	actin	N	B-AdverseReaction
keratosis	NN	keratosis	keratosis	keratosi	Y	I-AdverseReaction

15	CD	15	15	15	N	O
0	CD	0	0	0	N	O
7	CD	7	7	7	N	O
0	CD	0	0	0	N	O
9	CD	9	9	9	N	O
0	CD	0	0	0	N	O

Erythema	NN	erythema	erythema	erythema	Y	B-AdverseReaction

15	CD	15	15	15	N	O
0	CD	0	0	0	N	O
6	CD	6	6	6	N	O
0	CD	0	0	0	N	O
2	CD	2	2	2	N	O
0	CD	0	0	0	N	O

Pruritus	NN	pruritus	pruritus	pruritu	Y	B-AdverseReaction

11	CD	11	11	11	N	O
0	CD	0	0	0	N	O
11	CD	11	11	11	N	O
0	CD	0	0	0	N	O
13	CD	13	13	13	N	O
0	CD	0	0	0	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
disorders	NNS	disorders	disorder	disord	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction

44	CD	44	44	44	N	O
2	CD	2	2	2	N	O
46	CD	46	46	46	N	O
6	CD	6	6	6	N	O
21	CD	21	21	21	N	O
0	CD	0	0	0	N	O

Vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction

40	CD	40	40	40	N	O
2	CD	2	2	2	N	O
43	CD	43	43	43	N	O
4	CD	4	4	4	N	O
15	CD	15	15	15	N	O
0	CD	0	0	0	N	O

Diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction

36	CD	36	36	36	N	O
2	CD	2	2	2	N	O
26	CD	26	26	26	N	O
0	CD	0	0	0	N	O
28	CD	28	28	28	N	O
0	CD	0	0	0	N	O

Abdominal	NNP	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
d	NN	d	d	d	N	O

33	CD	33	33	33	N	O
2	CD	2	2	2	N	O
24	CD	24	24	24	N	O
2	CD	2	2	2	N	O
21	CD	21	21	21	N	O
2	CD	2	2	2	N	O

Constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction

22	CD	22	22	22	N	O
0	CD	0	0	0	N	O
17	CD	17	17	17	N	O
2	CD	2	2	2	N	O
11	CD	11	11	11	N	O
0	CD	0	0	0	N	O

Dry	NNP	dry	dry	dri	N	B-AdverseReaction
mouth	NN	mouth	mouth	mouth	N	I-AdverseReaction

11	CD	11	11	11	N	O
0	CD	0	0	0	N	O
11	CD	11	11	11	N	O
0	CD	0	0	0	N	O
6	CD	6	6	6	N	O
0	CD	0	0	0	N	O

Nervous	JJ	nervous	nervous	nervou	Y	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O

Headache	NN	headache	headache	headach	Y	B-AdverseReaction

29	CD	29	29	29	N	O
0	CD	0	0	0	N	O
37	CD	37	37	37	N	O
2	CD	2	2	2	N	O
28	CD	28	28	28	N	O
0	CD	0	0	0	N	O

Dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction

16	CD	16	16	16	N	O
0	CD	0	0	0	N	O
13	CD	13	13	13	N	O
0	CD	0	0	0	N	O
9	CD	9	9	9	N	O
0	CD	0	0	0	N	O

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
thoracic	NN	thoracic	thoracic	thorac	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
mediastinal	JJ	mediastinal	mediastinal	mediastin	N	O
disorders	NNS	disorders	disorder	disord	N	O

Cough	NN	cough	cough	cough	Y	B-AdverseReaction

29	CD	29	29	29	N	O
0	CD	0	0	0	N	O
11	CD	11	11	11	N	O
0	CD	0	0	0	N	O
21	CD	21	21	21	N	O
0	CD	0	0	0	N	O

Oropharyngeal	NNP	oropharyngeal	oropharyngeal	oropharyng	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction

13	CD	13	13	13	N	O
0	CD	0	0	0	N	O
7	CD	7	7	7	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	O
,	,	,	,	,	N	O
connective	JJ	connective	connective	connect	N	O
tissue	NN	tissue	tissue	tissu	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
bone	NN	bone	bone	bone	N	O
disorders	NNS	disorders	disorder	disord	N	O

Arthralgia	NN	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction

27	CD	27	27	27	N	O
0	CD	0	0	0	N	O
44	CD	44	44	44	N	O
0	CD	0	0	0	N	O
34	CD	34	34	34	N	O
0	CD	0	0	0	N	O

Myalgia	NN	myalgia	myalgia	myalgia	Y	B-AdverseReaction

22	CD	22	22	22	N	O
2	CD	2	2	2	N	O
24	CD	24	24	24	N	O
0	CD	0	0	0	N	O
23	CD	23	23	23	N	O
2	CD	2	2	2	N	O

Back	RB	back	back	back	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction

18	CD	18	18	18	N	O
5	CD	5	5	5	N	O
11	CD	11	11	11	N	O
0	CD	0	0	0	N	O
11	CD	11	11	11	N	O
2	CD	2	2	2	N	O

Muscle	NN	muscle	muscle	muscl	N	B-AdverseReaction
spasms	NNS	spasms	spasm	spasm	Y	I-AdverseReaction

16	CD	16	16	16	N	O
0	CD	0	0	0	N	O
2	CD	2	2	2	N	O
0	CD	0	0	0	N	O
4	CD	4	4	4	N	O
0	CD	0	0	0	N	O

Pain	NN	pain	pain	pain	Y	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
extremity	NN	extremity	extremity	extrem	N	I-AdverseReaction

16	CD	16	16	16	N	O
0	CD	0	0	0	N	O
11	CD	11	11	11	N	O
2	CD	2	2	2	N	O
19	CD	19	19	19	N	O
0	CD	0	0	0	N	O

Metabolism	NN	metabolism	metabolism	metabol	N	O
and	CC	and	and	and	N	O
nutritional	JJ	nutritional	nutritional	nutrit	N	O
disorders	NNS	disorders	disorder	disord	N	O

Decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
appetite	NN	appetite	appetite	appetit	N	I-AdverseReaction

22	CD	22	22	22	N	O
0	CD	0	0	0	N	O
30	CD	30	30	30	N	O
0	CD	0	0	0	N	O
19	CD	19	19	19	N	O
0	CD	0	0	0	N	O

Dehydration	NN	dehydration	dehydration	dehydr	Y	B-AdverseReaction

11	CD	11	11	11	N	O
0	CD	0	0	0	N	O
6	CD	6	6	6	N	O
2	CD	2	2	2	N	O
2	CD	2	2	2	N	O
0	CD	0	0	0	N	O

Psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Insomnia	NN	insomnia	insomnia	insomnia	Y	B-AdverseReaction

18	CD	18	18	18	N	O
0	CD	0	0	0	N	O
11	CD	11	11	11	N	O
0	CD	0	0	0	N	O
8	CD	8	8	8	N	O
2	CD	2	2	2	N	O

Vascular	JJ	vascular	vascular	vascular	N	O
disorders	NNS	disorders	disorder	disord	N	O

Hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	B-AdverseReaction
e	NN	e	e	e	N	O

16	CD	16	16	16	N	O
5	CD	5	5	5	N	O
11	CD	11	11	11	N	O
0	CD	0	0	0	N	O
2	CD	2	2	2	N	O
0	CD	0	0	0	N	O

Infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
infestations	NNS	infestations	infestation	infest	N	O

Urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction

13	CD	13	13	13	N	O
2	CD	2	2	2	N	O
6	CD	6	6	6	N	O
0	CD	0	0	0	N	O
9	CD	9	9	9	N	O
2	CD	2	2	2	N	O

Renal	NNP	renal	renal	renal	N	O
and	CC	and	and	and	N	O
urinary	JJ	urinary	urinary	urinari	N	O
disorders	NNS	disorders	disorder	disord	N	O

Renal	JJ	renal	renal	renal	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
f	NN	f	f	f	N	O

7	CD	7	7	7	N	O
7	CD	7	7	7	N	O
2	CD	2	2	2	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

a	DT	a	a	a	N	O
National	NNP	national	national	nation	N	O
Cancer	NNP	cancer	cancer	cancer	Y	O
Institute	NNP	institute	institute	institut	N	O
Common	NNP	common	common	common	N	O
Terminology	NNP	terminology	terminology	terminolog	N	O
Criteria	NNP	criteria	criterion	criteria	N	O
for	IN	for	for	for	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Events	NNP	events	event	event	N	O
,	,	,	,	,	N	O
version	NN	version	version	version	N	O
4	CD	4	4	4	N	O
.	.	.	.	.	N	O

b	NN	b	b	b	N	O

Includes	VBZ	includes	includes	includ	N	O
the	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
terms	NNS	terms	term	term	N	O
:	:	:	:	:	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
,	,	,	,	,	N	O
edema	NN	edema	edema	edema	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
lymphedema	NN	lymphedema	lymphedema	lymphedema	Y	B-AdverseReaction
.	.	.	.	.	N	O

c	SYM	c	c	c	N	O
Includes	VBZ	includes	includes	includ	N	O
the	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
terms	NNS	terms	term	term	N	O
:	:	:	:	:	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
generalized	VBD	generalized	generalized	gener	N	I-AdverseReaction
,	,	,	,	,	N	O
rash	JJ	rash	rash	rash	Y	B-AdverseReaction
pruritic	NN	pruritic	pruritic	prurit	N	I-AdverseReaction
,	,	,	,	,	N	O
rash	VBP	rash	rash	rash	Y	B-AdverseReaction
erythematous	JJ	erythematous	erythematous	erythemat	N	I-AdverseReaction
,	,	,	,	,	N	O
rash	JJ	rash	rash	rash	Y	B-AdverseReaction
papular	NN	papular	papular	papular	N	I-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
vesicular	NN	vesicular	vesicular	vesicular	N	I-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
macular	NN	macular	macular	macular	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
maculo	NN	maculo	maculo	maculo	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
papular	NN	papular	papular	papular	N	I-AdverseReaction
.	.	.	.	.	N	O

d	NN	d	d	d	N	O
Includes	VBZ	includes	includes	includ	N	O
the	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
terms	NNS	terms	term	term	N	O
:	:	:	:	:	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
upper	JJ	upper	upper	upper	N	I-AdverseReaction
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
lower	JJR	lower	lower	lower	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
discomfort	NN	discomfort	discomfort	discomfort	Y	I-AdverseReaction
.	.	.	.	.	N	O

e	NN	e	e	e	N	O
Includes	VBZ	includes	includes	includ	N	O
the	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
terms	NNS	terms	term	term	N	O
:	:	:	:	:	N	O
brain	NN	brain	brain	brain	N	B-AdverseReaction
stem	NN	stem	stem	stem	N	I-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
,	,	,	,	,	N	O
cerebral	JJ	cerebral	cerebral	cerebr	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
,	,	,	,	,	N	O
gastric	JJ	gastric	gastric	gastric	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
,	,	,	,	,	N	O
epistaxis	NN	epistaxis	epistaxis	epistaxi	Y	B-AdverseReaction
,	,	,	,	,	N	O
gingival	JJ	gingival	gingival	gingiv	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
,	,	,	,	,	N	O
hematuria	NN	hematuria	hematuria	hematuria	Y	B-AdverseReaction
,	,	,	,	,	N	O
vaginal	JJ	vaginal	vaginal	vagin	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
,	,	,	,	,	N	O
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	B-AdverseReaction
intracranial	JJ	intracranial	intracranial	intracrani	N	I-AdverseReaction
,	,	,	,	,	N	O
eye	NN	eye	eye	eye	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
vitreous	JJ	vitreous	vitreous	vitreou	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
.	.	.	.	.	N	O

f	NN	f	f	f	N	O
Includes	VBZ	includes	includes	includ	N	O
the	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
terms	NNS	terms	term	term	N	O
:	:	:	:	:	N	O
renal	JJ	renal	renal	renal	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
and	CC	and	and	and	N	O
renal	JJ	renal	renal	renal	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
acute	NN	acute	acute	acut	N	I-AdverseReaction
.	.	.	.	.	N	O

Other	JJ	other	other	other	N	O
clinically	RB	clinically	clinically	clinic	N	O
important	JJ	important	important	import	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
202	CD	202	202	202	N	O
)	)	)	)	)	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
10%	CD	10%	10%	10%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NNS	trametinib	trametinib	trametinib	N	O
were	VBD	were	were	were	N	O
:	:	:	:	:	N	O

Eye	JJ	eye	eye	eye	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Vision	NN	vision	vision	vision	N	B-AdverseReaction
blurred	VBD	blurred	blurred	blur	N	I-AdverseReaction
,	,	,	,	,	N	O
transient	JJ	transient	transient	transient	N	B-AdverseReaction
blindness	NN	blindness	blindness	blind	Y	I-AdverseReaction
.	.	.	.	.	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Stomatitis	NN	stomatitis	stomatitis	stomat	Y	B-AdverseReaction
,	,	,	,	,	N	O
pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	B-AdverseReaction
.	.	.	.	.	N	O

General	NNP	general	general	gener	N	O
Disorders	NNP	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
Site	NNP	site	site	site	N	O
Conditions	NNS	conditions	condition	condit	N	O
:	:	:	:	:	N	O
Asthenia	NNP	asthenia	asthenia	asthenia	Y	B-AdverseReaction
.	.	.	.	.	N	O

Infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
Infestations	NNS	infestations	infestation	infest	N	O
:	:	:	:	:	N	O
Cellulitis	NN	cellulitis	cellulitis	cellul	Y	B-AdverseReaction
,	,	,	,	,	N	O
folliculitis	NN	folliculitis	folliculitis	follicul	Y	B-AdverseReaction
,	,	,	,	,	N	O
paronychia	NN	paronychia	paronychia	paronychia	Y	B-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
pustular	NN	pustular	pustular	pustular	N	I-AdverseReaction
.	.	.	.	.	N	O

Neoplasms	NNP	neoplasms	neoplasm	neoplasm	N	O
Benign	NNP	benign	benign	benign	N	O
,	,	,	,	,	N	O
Malignant	NNP	malignant	malignant	malign	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
Unspecified	NNP	unspecified	unspecified	unspecifi	N	O
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
cysts	NNS	cysts	cyst	cyst	N	O
and	CC	and	and	and	N	O
polyps	NNS	polyps	polyp	polyp	Y	O
)	)	)	)	)	N	O
:	:	:	:	:	N	O
Skin	NNP	skin	skin	skin	N	B-AdverseReaction
papilloma	NN	papilloma	papilloma	papilloma	Y	I-AdverseReaction
.	.	.	.	.	N	O

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
Subcutaneous	NNP	subcutaneous	subcutaneous	subcutan	N	O
Tissue	NNP	tissue	tissue	tissu	N	O
Disorders	NNP	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Palmar	NNP	palmar	palmar	palmar	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
plantar	NN	plantar	plantar	plantar	N	I-AdverseReaction
erythrodysesthesia	JJ	erythrodysesthesia	erythrodysesthesia	erythrodysesthesia	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
,	,	,	,	,	N	O
hyperkeratosis	NN	hyperkeratosis	hyperkeratosis	hyperkeratosi	Y	B-AdverseReaction
,	,	,	,	,	N	O
hyperhidrosis	NN	hyperhidrosis	hyperhidrosis	hyperhidrosi	Y	B-AdverseReaction
.	.	.	.	.	N	O

Vascular	JJ	vascular	vascular	vascular	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Hypertension	NN	hypertension	hypertension	hypertens	Y	B-AdverseReaction
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
6	CD	6	6	6	N	O
.	.	.	.	.	N	O

Treatment	NNP	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
Emergent	JJ	emergent	emergent	emerg	N	O
Laboratory	NNP	laboratory	laboratory	laboratori	N	O
Abnormalities	NNPS	abnormalities	abnormality	abnorm	N	O
Occurring	NNP	occurring	occurring	occur	N	O
at	IN	at	at	at	N	O
10%	CD	10%	10%	10%	N	O
(	(	(	(	(	N	O
All	NNP	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
2%	CD	2%	2%	2%	N	O
(	(	(	(	(	N	O
Grades	NNP	grades	grade	grade	N	O
3	CD	3	3	3	N	O
or	CC	or	or	or	N	O
4	CD	4	4	4	N	O
)]	NNS	)]	)]	)]	N	O
of	IN	of	of	of	N	O
Patients	NNS	patients	patient	patient	N	O
Treated	VBN	treated	treated	treat	N	O
With	IN	with	with	with	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
in	IN	in	in	in	N	O
Combination	NNP	combination	combination	combin	N	O
With	IN	with	with	with	N	O
Trametinib	NNP	trametinib	trametinib	trametinib	N	O
in	IN	in	in	in	N	O
Trial	NNP	trial	trial	trial	N	O
2	CD	2	2	2	N	O

Tests	NNS	tests	test	test	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
plus	CC	plus	plus	plu	N	O
Trametinib	NNP	trametinib	trametinib	trametinib	N	O
2	CD	2	2	2	N	O
mg	NN	mg	mg	mg	N	O
N	NNP	n	n	n	N	O
55	CD	55	55	55	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
plus	CC	plus	plus	plu	N	O
Trametinib	NNP	trametinib	trametinib	trametinib	N	O
1	CD	1	1	1	N	O
mg	NN	mg	mg	mg	N	O
N	NNP	n	n	n	N	O
54	CD	54	54	54	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
N	NNP	n	n	n	N	O
53	CD	53	53	53	N	O

All	DT	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
Grades	NNP	grades	grade	grade	N	O
3	CD	3	3	3	N	O
and	CC	and	and	and	N	O
4	CD	4	4	4	N	O
All	NNP	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
Grades	NNP	grades	grade	grade	N	O
3	CD	3	3	3	N	O
and	CC	and	and	and	N	O
4	CD	4	4	4	N	O
All	NNP	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
Grades	NNP	grades	grade	grade	N	O
3	CD	3	3	3	N	O
and	CC	and	and	and	N	O
4	CD	4	4	4	N	O
a	DT	a	a	a	N	O

Hematology	NN	hematology	hematology	hematolog	N	O

Leukopenia	NNP	leukopenia	leukopenia	leukopenia	Y	B-AdverseReaction

62	CD	62	62	62	N	O
5	CD	5	5	5	N	O
46	CD	46	46	46	N	O
4	CD	4	4	4	N	O
21	CD	21	21	21	N	O
0	CD	0	0	0	N	O

Lymphopenia	NNP	lymphopenia	lymphopenia	lymphopenia	Y	B-AdverseReaction

55	CD	55	55	55	N	O
22	CD	22	22	22	N	O
59	CD	59	59	59	N	O
19	CD	19	19	19	N	O
40	CD	40	40	40	N	O
6	CD	6	6	6	N	O

Neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction

55	CD	55	55	55	N	O
13	CD	13	13	13	N	O
37	CD	37	37	37	N	O
2	CD	2	2	2	N	O
9	CD	9	9	9	N	O
2	CD	2	2	2	N	O

Anemia	NN	anemia	anemia	anemia	Y	B-AdverseReaction

55	CD	55	55	55	N	O
4	CD	4	4	4	N	O
46	CD	46	46	46	N	O
7	CD	7	7	7	N	O
28	CD	28	28	28	N	O
0	CD	0	0	0	N	O

Thrombocytopenia	NN	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	B-AdverseReaction

31	CD	31	31	31	N	O
4	CD	4	4	4	N	O
31	CD	31	31	31	N	O
2	CD	2	2	2	N	O
8	CD	8	8	8	N	O
0	CD	0	0	0	N	O

Liver	NNP	liver	liver	liver	N	O
Function	NNP	function	function	function	N	O
Tests	NNS	tests	test	test	N	O

Increased	VBN	increased	increased	increas	N	B-AdverseReaction
AST	NN	ast	ast	ast	N	I-AdverseReaction

60	CD	60	60	60	N	O
5	CD	5	5	5	N	O
54	CD	54	54	54	N	O
0	CD	0	0	0	N	O
15	CD	15	15	15	N	O
0	CD	0	0	0	N	O

Increased	VBN	increased	increased	increas	N	B-AdverseReaction
alkaline	JJ	alkaline	alkaline	alkalin	N	I-AdverseReaction
phosphatase	NN	phosphatase	phosphatase	phosphatas	N	I-AdverseReaction

60	CD	60	60	60	N	O
2	CD	2	2	2	N	O
67	CD	67	67	67	N	O
6	CD	6	6	6	N	O
26	CD	26	26	26	N	O
2	CD	2	2	2	N	O

Increased	VBN	increased	increased	increas	N	B-AdverseReaction
ALT	NN	alt	alt	alt	N	I-AdverseReaction

42	CD	42	42	42	N	O
4	CD	4	4	4	N	O
35	CD	35	35	35	N	O
4	CD	4	4	4	N	O
11	CD	11	11	11	N	O
0	CD	0	0	0	N	O

Hyperbilirubinemia	NN	hyperbilirubinemia	hyperbilirubinemia	hyperbilirubinemia	Y	B-AdverseReaction

15	CD	15	15	15	N	O
0	CD	0	0	0	N	O
7	CD	7	7	7	N	O
4	CD	4	4	4	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Chemistry	NN	chemistry	chemistry	chemistri	N	O

Hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction

58	CD	58	58	58	N	O
5	CD	5	5	5	N	O
67	CD	67	67	67	N	O
6	CD	6	6	6	N	O
49	CD	49	49	49	N	O
2	CD	2	2	2	N	O

Increased	VBN	increased	increased	increas	N	B-AdverseReaction
GGT	NN	ggt	ggt	ggt	Y	I-AdverseReaction

56	CD	56	56	56	N	O
11	CD	11	11	11	N	O
54	CD	54	54	54	N	O
17	CD	17	17	17	N	O
38	CD	38	38	38	N	O
2	CD	2	2	2	N	O

Hyponatremia	NN	hyponatremia	hyponatremia	hyponatremia	Y	B-AdverseReaction

55	CD	55	55	55	N	O
11	CD	11	11	11	N	O
48	CD	48	48	48	N	O
15	CD	15	15	15	N	O
36	CD	36	36	36	N	O
2	CD	2	2	2	N	O

Hypoalbuminemia	NN	hypoalbuminemia	hypoalbuminemia	hypoalbuminemia	Y	B-AdverseReaction

53	CD	53	53	53	N	O
0	CD	0	0	0	N	O
43	CD	43	43	43	N	O
2	CD	2	2	2	N	O
23	CD	23	23	23	N	O
0	CD	0	0	0	N	O

Hypophosphatemia	NN	hypophosphatemia	hypophosphatemia	hypophosphatemia	Y	B-AdverseReaction

47	CD	47	47	47	N	O
5	CD	5	5	5	N	O
41	CD	41	41	41	N	O
11	CD	11	11	11	N	O
40	CD	40	40	40	N	O
0	CD	0	0	0	N	O

Hypokalemia	NN	hypokalemia	hypokalemia	hypokalemia	Y	B-AdverseReaction

29	CD	29	29	29	N	O
2	CD	2	2	2	N	O
15	CD	15	15	15	N	O
2	CD	2	2	2	N	O
23	CD	23	23	23	N	O
6	CD	6	6	6	N	O

Increased	VBN	increased	increased	increas	N	B-AdverseReaction
creatinine	NN	creatinine	creatinine	creatinin	Y	I-AdverseReaction

24	CD	24	24	24	N	O
5	CD	5	5	5	N	O
20	CD	20	20	20	N	O
2	CD	2	2	2	N	O
9	CD	9	9	9	N	O
0	CD	0	0	0	N	O

Hypomagnesemia	NN	hypomagnesemia	hypomagnesemia	hypomagnesemia	Y	B-AdverseReaction

18	CD	18	18	18	N	O
2	CD	2	2	2	N	O
2	CD	2	2	2	N	O
0	CD	0	0	0	N	O
6	CD	6	6	6	N	O
0	CD	0	0	0	N	O

Hyperkalemia	NN	hyperkalemia	hyperkalemia	hyperkalemia	Y	B-AdverseReaction

18	CD	18	18	18	N	O
0	CD	0	0	0	N	O
22	CD	22	22	22	N	O
0	CD	0	0	0	N	O
15	CD	15	15	15	N	O
4	CD	4	4	4	N	O

Hypercalcemia	NN	hypercalcemia	hypercalcemia	hypercalcemia	Y	B-AdverseReaction

15	CD	15	15	15	N	O
0	CD	0	0	0	N	O
19	CD	19	19	19	N	O
2	CD	2	2	2	N	O
4	CD	4	4	4	N	O
0	CD	0	0	0	N	O

Hypocalcemia	NN	hypocalcemia	hypocalcemia	hypocalcemia	Y	B-AdverseReaction

13	CD	13	13	13	N	O
0	CD	0	0	0	N	O
20	CD	20	20	20	N	O
0	CD	0	0	0	N	O
9	CD	9	9	9	N	O
0	CD	0	0	0	N	O

a	DT	a	a	a	N	O
No	NNP	no	no	no	N	O
Grade	NNP	grade	grade	grade	N	O
4	CD	4	4	4	N	O
events	NNS	events	event	event	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
single	JJ	single	single	singl	N	O
agent	NN	agent	agent	agent	N	O
.	.	.	.	.	N	O

ALT	NN	alt	alt	alt	N	O

Alanine	NNP	alanine	alanine	alanin	N	O
aminotransferase	NN	aminotransferase	aminotransferase	aminotransferas	N	O
;	:	;	;	;	N	O
AST	NNP	ast	ast	ast	N	O
Aspartate	NNP	aspartate	aspartate	aspart	N	O
aminotransferase	NN	aminotransferase	aminotransferase	aminotransferas	N	O
;	:	;	;	;	N	O
GGT	NNP	ggt	ggt	ggt	Y	O
Gamma	NNP	gamma	gamma	gamma	N	O
glutamyltransferase	NN	glutamyltransferase	glutamyltransferase	glutamyltransferas	N	O
.	.	.	.	.	N	O

QT	JJ	qt	qt	qt	N	O
Prolongation	NN	prolongation	prolongation	prolong	N	O
:	:	:	:	:	N	O
In	IN	in	in	in	N	O
Trial	NNP	trial	trial	trial	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
QTcF	NNP	qtcf	qtcf	qtcf	N	B-AdverseReaction
prolongation	NN	prolongation	prolongation	prolong	N	I-AdverseReaction
to	TO	to	to	to	N	O
500	CD	500	500	500	N	B-Severity
msec	NNS	msec	msec	msec	N	I-Severity
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
4%	CD	4%	4%	4%	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
55	CD	55	55	55	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
2%	CD	2%	2%	2%	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
53	CD	53	53	53	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
single	JJ	single	single	singl	N	O
agent	NN	agent	agent	agent	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
QTcF	NNP	qtcf	qtcf	qtcf	N	B-AdverseReaction
was	VBD	was	wa	wa	N	I-AdverseReaction
increased	VBN	increased	increased	increas	N	I-AdverseReaction
more	JJR	more	more	more	N	O
than	IN	than	than	than	N	O
60	CD	60	60	60	N	B-Severity
msec	NN	msec	msec	msec	N	I-Severity
from	IN	from	from	from	N	I-Severity
baseline	NN	baseline	baseline	baselin	N	I-Severity
in	IN	in	in	in	N	O
13%	CD	13%	13%	13%	N	O
(	(	(	(	(	N	O
7	CD	7	7	7	N	O
55	CD	55	55	55	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
and	CC	and	and	and	N	O
2%	CD	2%	2%	2%	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
53	CD	53	53	53	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
single	JJ	single	single	singl	N	O
agent	NN	agent	agent	agent	N	O
.	.	.	.	.	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

Review	VB	review	review	review	N	O
the	DT	the	the	the	N	O
Full	NNP	full	full	full	N	O
Prescribing	NNP	prescribing	prescribing	prescrib	N	O
Information	NNP	information	information	inform	N	O
for	IN	for	for	for	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
following	VBG	following	following	follow	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
of	IN	of	of	of	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
single	JJ	single	single	singl	N	O
agent	NN	agent	agent	agent	N	O
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
may	MD	may	may	may	N	O
occur	VB	occur	occur	occur	N	O
when	WRB	when	when	when	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
is	VBZ	is	is	is	N	O
used	VBN	used	used	use	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
,	,	,	,	,	N	O
are	VBP	are	are	are	N	O
not	RB	not	not	not	N	O
described	VBN	described	described	describ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Full	NNP	full	full	full	N	O
Prescribing	NNP	prescribing	prescribing	prescrib	N	O
Information	NNP	information	information	inform	N	O
for	IN	for	for	for	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
:	:	:	:	:	N	O

Retinal	JJ	retinal	retinal	retin	N	B-AdverseReaction
vein	NN	vein	vein	vein	N	I-AdverseReaction
occlusion	NN	occlusion	occlusion	occlus	N	I-AdverseReaction

Interstitial	JJ	interstitial	interstitial	interstiti	N	B-AdverseReaction
lung	NN	lung	lung	lung	N	I-AdverseReaction
disease	NN	disease	disease	diseas	N	I-AdverseReaction

New	NNP	new	new	new	N	O
primary	JJ	primary	primary	primari	N	B-AdverseReaction
malignancies	NNS	malignancies	malignancy	malign	N	I-AdverseReaction
,	,	,	,	,	N	I-AdverseReaction
cutaneous	JJ	cutaneous	cutaneous	cutan	N	I-AdverseReaction
and	CC	and	and	and	N	O
non	JJ	non	non	non	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
cutaneous	JJ	cutaneous	cutaneous	cutan	N	I-AdverseReaction
,	,	,	,	,	N	O
can	MD	can	can	can	N	B-Factor
occur	VB	occur	occur	occur	N	O
when	WRB	when	when	when	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
is	VBZ	is	is	is	N	O
administered	VBN	administered	administered	administ	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
single	JJ	single	single	singl	N	O
agent	NN	agent	agent	agent	N	O
or	CC	or	or	or	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
.	.	.	.	.	N	O

Monitor	NN	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
for	IN	for	for	for	N	O
new	JJ	new	new	new	N	O
malignancies	NNS	malignancies	malignancy	malign	N	O
prior	VBP	prior	prior	prior	N	O
to	TO	to	to	to	N	O
initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
therapy	NN	therapy	therapy	therapi	N	O
,	,	,	,	,	N	O
while	IN	while	while	while	N	O
on	IN	on	on	on	N	O
therapy	NN	therapy	therapy	therapi	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
following	VBG	following	following	follow	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
or	CC	or	or	or	N	O
the	DT	the	the	the	N	O
combination	NN	combination	combination	combin	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
,	,	,	,	,	N	O
2.3	CD	2.3	2.3	2.3	N	O
)	)	)	)	)	N	O

Tumor	NN	tumor	tumor	tumor	N	B-AdverseReaction
Promotion	NNP	promotion	promotion	promot	Y	I-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
BRAF	NNP	braf	braf	braf	N	I-AdverseReaction
Wild	NNP	wild	wild	wild	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
Type	NN	type	type	type	N	I-AdverseReaction
Melanoma	NN	melanoma	melanoma	melanoma	Y	I-AdverseReaction
:	:	:	:	:	N	O
Increased	VBN	increased	increased	increas	N	B-AdverseReaction
cell	NN	cell	cell	cell	N	I-AdverseReaction
proliferation	NN	proliferation	proliferation	prolifer	N	I-AdverseReaction
can	MD	can	can	can	N	O
occur	VB	occur	occur	occur	N	O
with	IN	with	with	with	N	O
BRAF	NNP	braf	braf	braf	N	B-DrugClass
inhibitors	NNS	inhibitors	inhibitor	inhibitor	N	I-DrugClass
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O

Hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	B-AdverseReaction
:	:	:	:	:	N	O
Major	JJ	major	major	major	N	B-Severity
hemorrhagic	JJ	hemorrhagic	hemorrhagic	hemorrhag	N	B-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
can	MD	can	can	can	N	B-Factor
occur	VB	occur	occur	occur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
for	IN	for	for	for	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
bleeding	NN	bleeding	bleeding	bleed	Y	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O

Venous	JJ	venous	venous	venou	N	B-AdverseReaction
Thromboembolism	NN	thromboembolism	thromboembolism	thromboembol	Y	I-AdverseReaction
:	:	:	:	:	N	O
Deep	JJ	deep	deep	deep	N	B-AdverseReaction
vein	NN	vein	vein	vein	N	I-AdverseReaction
thrombosis	NN	thrombosis	thrombosis	thrombosi	Y	I-AdverseReaction
and	CC	and	and	and	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	B-AdverseReaction
embolism	NN	embolism	embolism	embol	Y	I-AdverseReaction
can	MD	can	can	can	N	B-Factor
occur	VB	occur	occur	occur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
,	,	,	,	,	N	O
2.3	CD	2.3	2.3	2.3	N	O
)	)	)	)	)	N	O

Cardiomyopathy	NN	cardiomyopathy	cardiomyopathy	cardiomyopathi	Y	B-AdverseReaction
:	:	:	:	:	N	O
Assess	NNP	assess	ass	assess	N	O
LVEF	NNP	lvef	lvef	lvef	N	O
before	IN	before	before	befor	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
,	,	,	,	,	N	O
after	IN	after	after	after	N	O
one	CD	one	one	one	N	O
month	NN	month	month	month	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
,	,	,	,	,	N	O
then	RB	then	then	then	N	O
every	DT	every	every	everi	N	O
2	CD	2	2	2	N	O
to	TO	to	to	to	N	O
3	CD	3	3	3	N	O
months	NNS	months	month	month	N	O
thereafter	RB	thereafter	thereafter	thereaft	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
,	,	,	,	,	N	O
2.3	CD	2.3	2.3	2.3	N	O
)	)	)	)	)	N	O

Ocular	JJ	ocular	ocular	ocular	N	B-AdverseReaction
Toxicities	NNS	toxicities	toxicity	toxic	N	I-AdverseReaction
:	:	:	:	:	N	O
Perform	NNP	perform	perform	perform	N	O
ophthalmologic	MD	ophthalmologic	ophthalmologic	ophthalmolog	N	O
evaluation	VB	evaluation	evaluation	evalu	N	O
for	IN	for	for	for	N	O
any	DT	any	any	ani	N	O
visual	JJ	visual	visual	visual	N	O
disturbances	NNS	disturbances	disturbance	disturb	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
,	,	,	,	,	N	O
2.3	CD	2.3	2.3	2.3	N	O
)	)	)	)	)	N	O

Serious	JJ	serious	serious	seriou	N	B-Severity
Febrile	NNP	febrile	febrile	febril	N	B-AdverseReaction
Reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
:	:	:	:	:	N	O
Incidence	NN	incidence	incidence	incid	N	O
and	CC	and	and	and	N	O
severity	NN	severity	severity	sever	N	O
of	IN	of	of	of	N	O
pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
are	VBP	are	are	are	N	O
increased	VBN	increased	increased	increas	N	O
with	IN	with	with	with	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.7	CD	5.7	5.7	5.7	N	O
,	,	,	,	,	N	O
2.3	CD	2.3	2.3	2.3	N	O
)	)	)	)	)	N	O

Serious	JJ	serious	serious	seriou	N	B-Severity
Skin	NNP	skin	skin	skin	N	B-AdverseReaction
Toxicity	NN	toxicity	toxicity	toxic	N	I-AdverseReaction
:	:	:	:	:	N	O
Monitor	NN	monitor	monitor	monitor	N	O
for	IN	for	for	for	N	O
skin	NN	skin	skin	skin	N	O
toxicities	NNS	toxicities	toxicity	toxic	N	O
and	CC	and	and	and	N	O
for	IN	for	for	for	N	O
secondary	JJ	secondary	secondary	secondari	N	O
infections	NNS	infections	infection	infect	N	O
.	.	.	.	.	N	O

Discontinue	NNP	discontinue	discontinue	discontinu	N	O
for	IN	for	for	for	N	O
intolerable	JJ	intolerable	intolerable	intoler	N	O
Grade	NNP	grade	grade	grade	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
Grade	VB	grade	grade	grade	N	O
3	CD	3	3	3	N	O
or	CC	or	or	or	N	O
4	CD	4	4	4	N	O
rash	NN	rash	rash	rash	Y	O
not	RB	not	not	not	N	O
improving	VBG	improving	improving	improv	N	O
within	IN	within	within	within	N	O
3	CD	3	3	3	N	O
weeks	NNS	weeks	week	week	N	O
despite	IN	despite	despite	despit	N	O
interruption	NN	interruption	interruption	interrupt	N	O
of	IN	of	of	of	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.8	CD	5.8	5.8	5.8	N	O
,	,	,	,	,	N	O
2.3	CD	2.3	2.3	2.3	N	O
)	)	)	)	)	N	O

Hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction
:	:	:	:	:	N	O
Monitor	NNP	monitor	monitor	monitor	N	O
serum	VBD	serum	serum	serum	N	O
glucose	JJ	glucose	glucose	glucos	Y	O
levels	NNS	levels	level	level	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
pre	JJ	pre	pre	pre	N	O
-	:	-	-	-	N	O
existing	VBG	existing	existing	exist	N	O
diabetes	NNS	diabetes	diabetes	diabet	Y	O
or	CC	or	or	or	N	O
hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.9	CD	5.9	5.9	5.9	N	O
)	)	)	)	)	N	O

Glucose	NNP	glucose	glucose	glucos	Y	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
6	CD	6	6	6	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
Phosphate	NN	phosphate	phosphate	phosphat	Y	I-AdverseReaction
Dehydrogenase	NNP	dehydrogenase	dehydrogenase	dehydrogenas	N	I-AdverseReaction
Deficiency	NNP	deficiency	deficiency	defici	N	I-AdverseReaction
:	:	:	:	:	N	O
Closely	RB	closely	closely	close	N	O
monitor	NN	monitor	monitor	monitor	N	O
for	IN	for	for	for	N	O
hemolytic	JJ	hemolytic	hemolytic	hemolyt	N	O
anemia	NN	anemia	anemia	anemia	Y	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.10	CD	5.10	5.10	5.10	N	O
)	)	)	)	)	N	O

Embryofetal	JJ	embryofetal	embryofetal	embryofet	N	B-AdverseReaction
Toxicity	NN	toxicity	toxicity	toxic	N	I-AdverseReaction
:	:	:	:	:	N	O
Can	MD	can	can	can	N	B-Factor
cause	VB	cause	cause	caus	N	O
fetal	JJ	fetal	fetal	fetal	N	B-AdverseReaction
harm	NN	harm	harm	harm	N	I-AdverseReaction
.	.	.	.	.	N	O

Advise	NNP	advise	advise	advis	N	O
females	NNS	females	female	femal	N	O
of	IN	of	of	of	N	O
reproductive	JJ	reproductive	reproductive	reproduct	N	O
potential	NN	potential	potential	potenti	N	O
of	IN	of	of	of	N	O
potential	JJ	potential	potential	potenti	N	O
risk	NN	risk	risk	risk	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
fetus	NN	fetus	fetus	fetu	N	O
.	.	.	.	.	N	O

TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
may	MD	may	may	may	N	O
render	VB	render	render	render	N	O
hormonal	JJ	hormonal	hormonal	hormon	N	O
contraceptives	NNS	contraceptives	contraceptive	contracept	N	O
less	RBR	less	le	less	N	O
effective	JJ	effective	effective	effect	N	O
and	CC	and	and	and	N	O
an	DT	an	an	an	N	O
alternative	JJ	alternative	alternative	altern	N	O
method	NN	method	method	method	N	O
of	IN	of	of	of	N	O
contraception	NN	contraception	contraception	contracept	Y	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
used	VBN	used	used	use	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.11	CD	5.11	5.11	5.11	N	O
,	,	,	,	,	N	O
8.1	CD	8.1	8.1	8.1	N	O
)	)	)	)	)	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O

5.1	CD	5.1	5.1	5.1	N	O

New	NNP	new	new	new	N	O
Primary	NNP	primary	primary	primari	N	O
Malignancies	NNS	malignancies	malignancy	malign	N	O

New	NNP	new	new	new	N	O
primary	JJ	primary	primary	primari	N	B-AdverseReaction
malignancies	NNS	malignancies	malignancy	malign	N	I-AdverseReaction
,	,	,	,	,	N	I-AdverseReaction
cutaneous	JJ	cutaneous	cutaneous	cutan	N	I-AdverseReaction
and	CC	and	and	and	N	O
non	JJ	non	non	non	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
cutaneous	JJ	cutaneous	cutaneous	cutan	N	I-AdverseReaction
,	,	,	,	,	N	O
can	MD	can	can	can	N	B-Factor
occur	VB	occur	occur	occur	N	O
when	WRB	when	when	when	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
is	VBZ	is	is	is	N	O
administered	VBN	administered	administered	administ	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
single	JJ	single	single	singl	N	O
agent	NN	agent	agent	agent	N	O
or	CC	or	or	or	N	O
when	WRB	when	when	when	N	O
used	VBN	used	used	use	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
.	.	.	.	.	N	O

Cutaneous	JJ	cutaneous	cutaneous	cutan	N	O
Malignancies	NNS	malignancies	malignancy	malign	N	O
:	:	:	:	:	N	O

TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
results	NNS	results	result	result	N	O
in	IN	in	in	in	N	O
an	DT	an	an	an	N	O
increased	JJ	increased	increased	increas	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
cutaneous	JJ	cutaneous	cutaneous	cutan	N	B-AdverseReaction
squamous	JJ	squamous	squamous	squamou	N	I-AdverseReaction
cell	NN	cell	cell	cell	N	I-AdverseReaction
carcinoma	NN	carcinoma	carcinoma	carcinoma	Y	I-AdverseReaction
,	,	,	,	,	N	O
keratoacanthoma	NN	keratoacanthoma	keratoacanthoma	keratoacanthoma	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
melanoma	NN	melanoma	melanoma	melanoma	Y	B-AdverseReaction
.	.	.	.	.	N	O

TAFINLAR	NN	tafinlar	tafinlar	tafinlar	N	O
when	WRB	when	when	when	N	O
used	VBN	used	used	use	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	JJ	trametinib	trametinib	trametinib	N	O
results	NNS	results	result	result	N	O
in	IN	in	in	in	N	O
an	DT	an	an	an	N	O
increased	JJ	increased	increased	increas	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
basal	NN	basal	basal	basal	N	B-AdverseReaction
cell	NN	cell	cell	cell	N	I-AdverseReaction
carcinoma	NN	carcinoma	carcinoma	carcinoma	Y	I-AdverseReaction
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
Trial	NNP	trial	trial	trial	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
cutaneous	JJ	cutaneous	cutaneous	cutan	N	B-AdverseReaction
squamous	JJ	squamous	squamous	squamou	N	I-AdverseReaction
cell	NN	cell	cell	cell	N	I-AdverseReaction
carcinomas	NN	carcinomas	carcinoma	carcinoma	N	I-AdverseReaction
and	CC	and	and	and	N	O
keratoacanthomas	NN	keratoacanthomas	keratoacanthoma	keratoacanthoma	N	B-AdverseReaction
(	(	(	(	(	N	O
cuSCC	NN	cuscc	cuscc	cuscc	N	B-AdverseReaction
)	)	)	)	)	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
7%	CD	7%	7%	7%	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
187	CD	187	187	187	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
none	NN	none	none	none	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
dacarbazine	NN	dacarbazine	dacarbazine	dacarbazin	N	O
.	.	.	.	.	N	O

Across	IN	across	across	across	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
586	CD	586	586	586	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
cuSCC	NN	cuscc	cuscc	cuscc	N	B-AdverseReaction
was	VBD	was	wa	wa	N	O
11%	CD	11%	11%	11%	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
time	NN	time	time	time	N	O
to	TO	to	to	to	N	O
first	VB	first	first	first	N	O
cuSCC	NN	cuscc	cuscc	cuscc	N	B-AdverseReaction
was	VBD	was	wa	wa	N	O
9	CD	9	9	9	N	O
weeks	NNS	weeks	week	week	N	O
(	(	(	(	(	N	O
range	NN	range	range	rang	N	O
:	:	:	:	:	N	O
1	CD	1	1	1	N	O
to	TO	to	to	to	N	O
53	CD	53	53	53	N	O
weeks	NNS	weeks	week	week	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Of	IN	of	of	of	N	O
those	DT	those	those	those	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
developed	VBD	developed	developed	develop	N	O
new	JJ	new	new	new	N	O
cuSCC	NN	cuscc	cuscc	cuscc	N	B-AdverseReaction
,	,	,	,	,	N	O
approximately	RB	approximately	approximately	approxim	N	O
33%	CD	33%	33%	33%	N	O
developed	VBD	developed	developed	develop	N	O
one	CD	one	one	one	N	O
or	CC	or	or	or	N	O
more	JJR	more	more	more	N	O
cuSCC	NNS	cuscc	cuscc	cuscc	N	B-AdverseReaction
with	IN	with	with	with	N	O
continued	JJ	continued	continued	continu	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
time	NN	time	time	time	N	O
between	IN	between	between	between	N	O
diagnosis	NN	diagnosis	diagnosis	diagnosi	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
cuSCC	NN	cuscc	cuscc	cuscc	N	B-AdverseReaction
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
second	JJ	second	second	second	N	O
cuSCC	NN	cuscc	cuscc	cuscc	N	B-AdverseReaction
was	VBD	was	wa	wa	N	O
6	CD	6	6	6	N	O
weeks	NNS	weeks	week	week	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
Trial	NNP	trial	trial	trial	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
new	JJ	new	new	new	N	O
primary	JJ	primary	primary	primari	N	B-AdverseReaction
malignant	JJ	malignant	malignant	malign	N	I-AdverseReaction
melanomas	NN	melanomas	melanoma	melanoma	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
2%	CD	2%	2%	2%	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
187	CD	187	187	187	N	O
)	)	)	)	)	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
while	IN	while	while	while	N	O
no	DT	no	no	no	N	O
dacarbazine	NN	dacarbazine	dacarbazine	dacarbazin	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patient	NN	patient	patient	patient	N	O
was	VBD	was	wa	wa	N	O
diagnosed	VBN	diagnosed	diagnosed	diagnos	N	O
with	IN	with	with	with	N	O
new	JJ	new	new	new	N	O
primary	JJ	primary	primary	primari	N	O
malignant	JJ	malignant	malignant	malign	N	O
melanoma	NN	melanoma	melanoma	melanoma	Y	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
Trial	NNP	trial	trial	trial	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
basal	NN	basal	basal	basal	N	B-AdverseReaction
cell	NN	cell	cell	cell	N	I-AdverseReaction
carcinoma	NN	carcinoma	carcinoma	carcinoma	Y	I-AdverseReaction
was	VBD	was	wa	wa	N	O
increased	VBN	increased	increased	increas	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
:	:	:	:	:	N	O
9%	CD	9%	9%	9%	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
55	CD	55	55	55	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NNS	trametinib	trametinib	trametinib	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
2%	CD	2%	2%	2%	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
53	CD	53	53	53	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
single	JJ	single	single	singl	N	O
agent	NN	agent	agent	agent	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
range	NN	range	range	rang	N	O
of	IN	of	of	of	N	O
time	NN	time	time	time	N	O
to	TO	to	to	to	N	O
diagnosis	NN	diagnosis	diagnosis	diagnosi	N	O
of	IN	of	of	of	N	O
basal	NN	basal	basal	basal	N	B-AdverseReaction
cell	NN	cell	cell	cell	N	I-AdverseReaction
carcinoma	NN	carcinoma	carcinoma	carcinoma	Y	I-AdverseReaction
was	VBD	was	wa	wa	N	O
28	CD	28	28	28	N	O
to	TO	to	to	to	N	O
249	CD	249	249	249	N	O
days	NNS	days	day	day	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
and	CC	and	and	and	N	O
was	VBD	was	wa	wa	N	O
197	CD	197	197	197	N	O
days	NNS	days	day	day	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
single	JJ	single	single	singl	N	O
agent	NN	agent	agent	agent	N	O
.	.	.	.	.	N	O

Cutaneous	JJ	cutaneous	cutaneous	cutan	N	B-AdverseReaction
squamous	JJ	squamous	squamous	squamou	N	I-AdverseReaction
cell	NN	cell	cell	cell	N	I-AdverseReaction
carcinoma	NN	carcinoma	carcinoma	carcinoma	Y	I-AdverseReaction
(	(	(	(	(	N	O
SCC	NNP	scc	scc	scc	N	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
keratoacanthoma	NN	keratoacanthoma	keratoacanthoma	keratoacanthoma	Y	B-AdverseReaction
,	,	,	,	,	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
7%	CD	7%	7%	7%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
and	CC	and	and	and	N	O
19%	CD	19%	19%	19%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
single	JJ	single	single	singl	N	O
agent	NN	agent	agent	agent	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
range	NN	range	range	rang	N	O
of	IN	of	of	of	N	O
time	NN	time	time	time	N	O
to	TO	to	to	to	N	O
diagnosis	NN	diagnosis	diagnosis	diagnosi	N	O
of	IN	of	of	of	N	O
cuSCC	NN	cuscc	cuscc	cuscc	N	B-AdverseReaction
was	VBD	was	wa	wa	N	O
136	CD	136	136	136	N	O
to197	JJ	to197	to197	to197	N	O
days	NNS	days	day	day	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
combination	NN	combination	combination	combin	N	O
arm	NN	arm	arm	arm	N	O
and	CC	and	and	and	N	O
was	VBD	was	wa	wa	N	O
9	CD	9	9	9	N	O
to	TO	to	to	to	N	O
197	CD	197	197	197	N	O
days	NNS	days	day	day	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
arm	NN	arm	arm	arm	N	O
receiving	NN	receiving	receiving	receiv	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
single	JJ	single	single	singl	N	O
agent	NN	agent	agent	agent	N	O
.	.	.	.	.	N	O

New	NNP	new	new	new	N	O
primary	JJ	primary	primary	primari	N	B-AdverseReaction
melanoma	NN	melanoma	melanoma	melanoma	Y	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
2%	CD	2%	2%	2%	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
53	CD	53	53	53	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
single	JJ	single	single	singl	N	O
agent	NN	agent	agent	agent	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
none	NN	none	none	none	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
55	CD	55	55	55	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
.	.	.	.	.	N	O

Perform	NNP	perform	perform	perform	N	O
dermatologic	JJ	dermatologic	dermatologic	dermatolog	N	O
evaluations	NNS	evaluations	evaluation	evalu	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
single	JJ	single	single	singl	N	O
agent	NN	agent	agent	agent	N	O
or	CC	or	or	or	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
,	,	,	,	,	N	O
every	DT	every	every	everi	N	O
2	CD	2	2	2	N	O
months	NNS	months	month	month	N	O
while	IN	while	while	while	N	O
on	IN	on	on	on	N	O
therapy	NN	therapy	therapy	therapi	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
for	IN	for	for	for	N	O
up	RB	up	up	up	N	O
to	TO	to	to	to	N	O
6	CD	6	6	6	N	O
months	NNS	months	month	month	N	O
following	VBG	following	following	follow	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
.	.	.	.	.	N	O

No	DT	no	no	no	N	O
dose	JJ	dose	dose	dose	N	O
modifications	NNS	modifications	modification	modif	N	O
of	IN	of	of	of	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
or	CC	or	or	or	N	O
trametinib	EX	trametinib	trametinib	trametinib	N	O
are	VBP	are	are	are	N	O
required	VBN	required	required	requir	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
develop	VBP	develop	develop	develop	N	O
new	JJ	new	new	new	N	O
primary	JJ	primary	primary	primari	N	O
cutaneous	JJ	cutaneous	cutaneous	cutan	N	O
malignancies	NNS	malignancies	malignancy	malign	N	O
.	.	.	.	.	N	O

Non	NNP	non	non	non	N	O
-	:	-	-	-	N	O
cutaneous	JJ	cutaneous	cutaneous	cutan	N	O
Malignancies	NNS	malignancies	malignancy	malign	N	O
:	:	:	:	:	N	O

Based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
its	PRP$	its	it	it	N	O
mechanism	NN	mechanism	mechanism	mechan	N	O
of	IN	of	of	of	N	O
action	NN	action	action	action	N	O
,	,	,	,	,	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
may	MD	may	may	may	N	B-Factor
promote	VB	promote	promote	promot	N	O
the	DT	the	the	the	N	O
growth	NN	growth	growth	growth	N	O
and	CC	and	and	and	N	O
development	NN	development	development	develop	N	O
of	IN	of	of	of	N	O
malignancies	NNS	malignancies	malignancy	malign	N	B-AdverseReaction
with	IN	with	with	with	N	O
activation	NN	activation	activation	activ	N	O
of	IN	of	of	of	N	O
RAS	NNP	ras	ra	ra	N	O
through	IN	through	through	through	N	O
mutation	NN	mutation	mutation	mutat	N	O
or	CC	or	or	or	N	O
other	JJ	other	other	other	N	O
mechanisms	NNS	mechanisms	mechanism	mechan	N	O
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	JJ	trametinib	trametinib	trametinib	N	O
four	CD	four	four	four	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
non	JJ	non	non	non	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
cutaneous	JJ	cutaneous	cutaneous	cutan	N	I-AdverseReaction
malignancies	NNS	malignancies	malignancy	malign	N	I-AdverseReaction
were	VBD	were	were	were	N	O
identified	VBN	identified	identified	identifi	N	O
:	:	:	:	:	N	O
KRAS	NNP	kras	kras	kra	N	B-AdverseReaction
mutation	NN	mutation	mutation	mutat	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
positive	JJ	positive	positive	posit	N	I-AdverseReaction
pancreatic	JJ	pancreatic	pancreatic	pancreat	N	I-AdverseReaction
adenocarcinoma	NN	adenocarcinoma	adenocarcinoma	adenocarcinoma	Y	I-AdverseReaction
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
recurrent	JJ	recurrent	recurrent	recurr	N	B-AdverseReaction
NRAS	NNP	nras	nra	nra	N	I-AdverseReaction
mutation	NN	mutation	mutation	mutat	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
positive	JJ	positive	positive	posit	N	I-AdverseReaction
colorectal	JJ	colorectal	colorectal	colorect	N	I-AdverseReaction
carcinoma	NN	carcinoma	carcinoma	carcinoma	Y	I-AdverseReaction
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
head	NN	head	head	head	N	B-AdverseReaction
and	CC	and	and	and	N	I-AdverseReaction
neck	NN	neck	neck	neck	N	I-AdverseReaction
carcinoma	NN	carcinoma	carcinoma	carcinoma	Y	I-AdverseReaction
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
glioblastoma	NN	glioblastoma	glioblastoma	glioblastoma	Y	B-AdverseReaction
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Monitor	NN	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
the	DT	the	the	the	N	O
combination	NN	combination	combination	combin	N	O
closely	RB	closely	closely	close	N	O
for	IN	for	for	for	N	O
signs	NNS	signs	sign	sign	N	O
or	CC	or	or	or	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
non	JJ	non	non	non	N	O
-	:	-	-	-	N	O
cutaneous	JJ	cutaneous	cutaneous	cutan	N	O
malignancies	NNS	malignancies	malignancy	malign	N	O
.	.	.	.	.	N	O

Permanently	RB	permanently	permanently	perman	N	O
discontinue	VBZ	discontinue	discontinue	discontinu	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
for	IN	for	for	for	N	O
RAS	NNP	ras	ra	ra	N	O
mutation	NN	mutation	mutation	mutat	N	O
-	:	-	-	-	N	O
positive	JJ	positive	positive	posit	N	O
non	NN	non	non	non	N	O
-	:	-	-	-	N	O
cutaneous	JJ	cutaneous	cutaneous	cutan	N	O
malignancies	NNS	malignancies	malignancy	malign	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
used	VBN	used	used	use	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
,	,	,	,	,	N	O
no	DT	no	no	no	N	O
dose	JJ	dose	dose	dose	N	O
modification	NN	modification	modification	modif	N	O
of	IN	of	of	of	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
is	VBZ	is	is	is	N	O
required	VBN	required	required	requir	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
develop	VBP	develop	develop	develop	N	O
non	JJ	non	non	non	N	O
-	:	-	-	-	N	O
cutaneous	JJ	cutaneous	cutaneous	cutan	N	O
malignancies	NNS	malignancies	malignancy	malign	N	O
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O
Tumor	NNP	tumor	tumor	tumor	N	O
Promotion	NNP	promotion	promotion	promot	Y	O
in	IN	in	in	in	N	O
BRAF	NNP	braf	braf	braf	N	O
Wild	NNP	wild	wild	wild	N	O
-	:	-	-	-	N	O
Type	NN	type	type	type	N	O
Melanoma	NN	melanoma	melanoma	melanoma	Y	O

In	IN	in	in	in	N	O
vitro	JJ	vitro	vitro	vitro	N	O
experiments	NNS	experiments	experiment	experi	N	O
have	VBP	have	have	have	N	O
demonstrated	VBN	demonstrated	demonstrated	demonstr	N	O
paradoxical	JJ	paradoxical	paradoxical	paradox	N	O
activation	NN	activation	activation	activ	N	O
of	IN	of	of	of	N	O
MAP	NNP	map	map	map	N	O
-	:	-	-	-	N	O
kinase	NN	kinase	kinase	kinas	N	O
signaling	NN	signaling	signaling	signal	N	O
and	CC	and	and	and	N	O
increased	VBD	increased	increased	increas	N	B-AdverseReaction
cell	NN	cell	cell	cell	N	I-AdverseReaction
proliferation	NN	proliferation	proliferation	prolifer	N	I-AdverseReaction
in	IN	in	in	in	N	O
BRAF	NNP	braf	braf	braf	N	O
wild	JJ	wild	wild	wild	N	O
-	:	-	-	-	N	O
type	NN	type	type	type	N	O
cells	NNS	cells	cell	cell	N	O
which	WDT	which	which	which	N	O
are	VBP	are	are	are	N	O
exposed	VBN	exposed	exposed	expos	N	O
to	TO	to	to	to	N	O
BRAF	NNP	braf	braf	braf	N	B-DrugClass
inhibitors	NNS	inhibitors	inhibitor	inhibitor	N	I-DrugClass
.	.	.	.	.	N	O

Confirm	NNP	confirm	confirm	confirm	N	O
evidence	NN	evidence	evidence	evid	N	O
of	IN	of	of	of	N	O
BRAF	NNP	braf	braf	braf	N	O
V600E	NNP	v600e	v600e	v600e	N	O
or	CC	or	or	or	N	O
V600K	NNP	v600k	v600k	v600k	N	O
mutation	NN	mutation	mutation	mutat	N	O
status	NN	status	status	statu	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
single	JJ	single	single	singl	N	O
agent	NN	agent	agent	agent	N	O
or	CC	or	or	or	N	O
combination	NN	combination	combination	combin	N	O
therapy	NN	therapy	therapy	therapi	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Indications	NNP	indications	indication	indic	N	O
and	CC	and	and	and	N	O
Usage	NNP	usage	usage	usag	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.1	CD	2.1	2.1	2.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
Hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	O

Hemorrhages	NNS	hemorrhages	hemorrhage	hemorrhag	N	B-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
major	JJ	major	major	major	N	B-Severity
hemorrhages	NNS	hemorrhages	hemorrhage	hemorrhag	N	B-AdverseReaction
defined	VBN	defined	defined	defin	N	O
as	IN	as	a	as	N	O
symptomatic	JJ	symptomatic	symptomatic	symptomat	N	B-AdverseReaction
bleeding	NN	bleeding	bleeding	bleed	Y	I-AdverseReaction
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
critical	JJ	critical	critical	critic	N	O
area	NN	area	area	area	N	O
or	CC	or	or	or	N	O
organ	NN	organ	organ	organ	N	O
,	,	,	,	,	N	O
can	MD	can	can	can	N	B-Factor
occur	VB	occur	occur	occur	N	O
when	WRB	when	when	when	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
is	VBZ	is	is	is	N	O
used	VBN	used	used	use	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
Trial	NNP	trial	trial	trial	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
resulted	VBD	resulted	resulted	result	N	O
in	IN	in	in	in	N	O
an	DT	an	an	an	N	O
increased	VBN	increased	increased	increas	N	O
incidence	NN	incidence	incidence	incid	N	O
and	CC	and	and	and	N	O
severity	NN	severity	severity	sever	N	O
of	IN	of	of	of	N	O
any	DT	any	any	ani	N	O
hemorrhagic	JJ	hemorrhagic	hemorrhagic	hemorrhag	N	B-AdverseReaction
event	NN	event	event	event	N	I-AdverseReaction
:	:	:	:	:	N	O
16%	CD	16%	16%	16%	N	O
(	(	(	(	(	N	O
9	CD	9	9	9	N	O
55	CD	55	55	55	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NNS	trametinib	trametinib	trametinib	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
2%	CD	2%	2%	2%	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
53	CD	53	53	53	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
single	JJ	single	single	singl	N	O
agent	NN	agent	agent	agent	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
major	JJ	major	major	major	N	B-Severity
hemorrhagic	JJ	hemorrhagic	hemorrhagic	hemorrhag	N	B-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
of	IN	of	of	of	N	O
intracranial	JJ	intracranial	intracranial	intracrani	N	B-AdverseReaction
or	CC	or	or	or	N	O
gastric	JJ	gastric	gastric	gastric	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
5%	CD	5%	5%	5%	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
55	CD	55	55	55	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NNS	trametinib	trametinib	trametinib	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
none	NN	none	none	none	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
53	CD	53	53	53	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
single	JJ	single	single	singl	N	O
agent	NN	agent	agent	agent	N	O
.	.	.	.	.	N	O

Intracranial	JJ	intracranial	intracranial	intracrani	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
was	VBD	was	wa	wa	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
in	IN	in	in	in	N	O
4%	CD	4%	4%	4%	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
55	CD	55	55	55	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
.	.	.	.	.	N	O

Permanently	RB	permanently	permanently	perman	N	O
discontinue	VBZ	discontinue	discontinue	discontinu	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
and	CC	and	and	and	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
for	IN	for	for	for	N	O
all	DT	all	all	all	N	O
Grade	NNP	grade	grade	grade	N	O
4	CD	4	4	4	N	O
hemorrhagic	JJ	hemorrhagic	hemorrhagic	hemorrhag	N	O
events	NNS	events	event	event	N	O
and	CC	and	and	and	N	O
for	IN	for	for	for	N	O
any	DT	any	any	ani	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
hemorrhagic	NN	hemorrhagic	hemorrhagic	hemorrhag	N	O
events	NNS	events	event	event	N	O
that	WDT	that	that	that	N	O
do	VBP	do	do	do	N	O
not	RB	not	not	not	N	O
improve	VB	improve	improve	improv	N	O
.	.	.	.	.	N	O

Withhold	NNP	withhold	withhold	withhold	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
for	IN	for	for	for	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
hemorrhagic	JJ	hemorrhagic	hemorrhagic	hemorrhag	N	O
events	NNS	events	event	event	N	O
;	:	;	;	;	N	O
if	IN	if	if	if	N	O
improved	VBN	improved	improved	improv	N	O
resume	NN	resume	resume	resum	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
lower	JJR	lower	lower	lower	N	O
dose	JJ	dose	dose	dose	N	O
level	NN	level	level	level	N	O
.	.	.	.	.	N	O

Withhold	NNP	withhold	withhold	withhold	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
for	IN	for	for	for	N	O
up	IN	up	up	up	N	O
to	TO	to	to	to	N	O
3	CD	3	3	3	N	O
weeks	NNS	weeks	week	week	N	O
for	IN	for	for	for	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
hemorrhagic	JJ	hemorrhagic	hemorrhagic	hemorrhag	N	O
events	NNS	events	event	event	N	O
;	:	;	;	;	N	O
if	IN	if	if	if	N	O
improved	VBN	improved	improved	improv	N	O
,	,	,	,	,	N	O
resume	VB	resume	resume	resum	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
lower	JJR	lower	lower	lower	N	O
dose	JJ	dose	dose	dose	N	O
level	NN	level	level	level	N	O
.	.	.	.	.	N	O

5.4	CD	5.4	5.4	5.4	N	O
Venous	JJ	venous	venous	venou	N	O
Thromboembolism	NN	thromboembolism	thromboembolism	thromboembol	Y	O

Venous	JJ	venous	venous	venou	N	B-AdverseReaction
thromboembolism	NN	thromboembolism	thromboembolism	thromboembol	Y	I-AdverseReaction
can	MD	can	can	can	N	B-Factor
occur	VB	occur	occur	occur	N	O
when	WRB	when	when	when	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
is	VBZ	is	is	is	N	O
used	VBN	used	used	use	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
Trial	NNP	trial	trial	trial	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
resulted	VBD	resulted	resulted	result	N	O
in	IN	in	in	in	N	O
an	DT	an	an	an	N	O
increased	JJ	increased	increased	increas	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
deep	JJ	deep	deep	deep	N	B-AdverseReaction
venous	JJ	venous	venous	venou	N	I-AdverseReaction
thrombosis	NN	thrombosis	thrombosis	thrombosi	Y	I-AdverseReaction
(	(	(	(	(	N	O
DVT	NNP	dvt	dvt	dvt	Y	B-AdverseReaction
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	B-AdverseReaction
embolism	NN	embolism	embolism	embol	Y	I-AdverseReaction
(	(	(	(	(	N	O
PE	NNP	pe	pe	pe	N	B-AdverseReaction
)	)	)	)	)	N	O
:	:	:	:	:	N	O
7%	CD	7%	7%	7%	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
55	CD	55	55	55	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NNS	trametinib	trametinib	trametinib	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
none	NN	none	none	none	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
53	CD	53	53	53	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
single	JJ	single	single	singl	N	O
agent	NN	agent	agent	agent	N	O
.	.	.	.	.	N	O

Pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	B-AdverseReaction
embolism	NN	embolism	embolism	embol	Y	I-AdverseReaction
was	VBD	was	wa	wa	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
in	IN	in	in	in	N	O
2%	CD	2%	2%	2%	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
55	CD	55	55	55	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
.	.	.	.	.	N	O

Advise	NN	advise	advise	advis	N	O
patients	NNS	patients	patient	patient	N	O
to	TO	to	to	to	N	O
immediately	RB	immediately	immediately	immedi	N	O
seek	VB	seek	seek	seek	N	O
medical	JJ	medical	medical	medic	N	O
care	NN	care	care	care	N	O
if	IN	if	if	if	N	O
they	PRP	they	they	they	N	O
develop	VBP	develop	develop	develop	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
DVT	NNP	dvt	dvt	dvt	Y	O
or	CC	or	or	or	N	O
PE	NNP	pe	pe	pe	N	O
,	,	,	,	,	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
shortness	NN	shortness	shortness	short	N	O
of	IN	of	of	of	N	O
breath	NN	breath	breath	breath	N	O
,	,	,	,	,	N	O
chest	NN	chest	chest	chest	N	O
pain	NN	pain	pain	pain	Y	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
arm	NN	arm	arm	arm	N	O
or	CC	or	or	or	N	O
leg	NN	leg	leg	leg	N	O
swelling	NN	swelling	swelling	swell	Y	O
.	.	.	.	.	N	O

Permanently	RB	permanently	permanently	perman	N	O
discontinue	VBZ	discontinue	discontinue	discontinu	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
and	CC	and	and	and	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
for	IN	for	for	for	N	O
life	NN	life	life	life	N	O
-	:	-	-	-	N	O
threatening	NN	threatening	threatening	threaten	N	O
PE	NNP	pe	pe	pe	N	O
.	.	.	.	.	N	O

Withhold	NNP	withhold	withhold	withhold	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
and	CC	and	and	and	N	O
continue	VB	continue	continue	continu	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
at	IN	at	at	at	N	O
the	DT	the	the	the	N	O
same	JJ	same	same	same	N	O
dose	NN	dose	dose	dose	N	O
for	IN	for	for	for	N	O
uncomplicated	JJ	uncomplicated	uncomplicated	uncompl	N	O
DVT	NNP	dvt	dvt	dvt	Y	O
or	CC	or	or	or	N	O
PE	NNP	pe	pe	pe	N	O
;	:	;	;	;	N	O
if	IN	if	if	if	N	O
improved	VBN	improved	improved	improv	N	O
within	IN	within	within	within	N	O
3	CD	3	3	3	N	O
weeks	NNS	weeks	week	week	N	O
,	,	,	,	,	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
resumed	VBN	resumed	resumed	resum	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
lower	JJR	lower	lower	lower	N	O
dose	JJ	dose	dose	dose	N	O
level	NN	level	level	level	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.3	CD	2.3	2.3	2.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.5	CD	5.5	5.5	5.5	N	O
Cardiomyopathy	NNP	cardiomyopathy	cardiomyopathy	cardiomyopathi	Y	O

Cardiomyopathy	NNP	cardiomyopathy	cardiomyopathy	cardiomyopathi	Y	B-AdverseReaction
can	MD	can	can	can	N	B-Factor
occur	VB	occur	occur	occur	N	O
when	WRB	when	when	when	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
is	VBZ	is	is	is	N	O
used	VBN	used	used	use	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
and	CC	and	and	and	N	O
with	IN	with	with	with	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
single	JJ	single	single	singl	N	O
agent	NN	agent	agent	agent	N	O
[	NNP	[	[	[	N	O
refer	NN	refer	refer	refer	N	O
to	TO	to	to	to	N	O
Full	NNP	full	full	full	N	O
Prescribing	NNP	prescribing	prescribing	prescrib	N	O
Information	NNP	information	information	inform	N	O
for	IN	for	for	for	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
Trial	NNP	trial	trial	trial	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
cardiomyopathy	NN	cardiomyopathy	cardiomyopathy	cardiomyopathi	Y	B-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
9%	CD	9%	9%	9%	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
55	CD	55	55	55	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
none	NN	none	none	none	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
single	JJ	single	single	singl	N	O
agent	NN	agent	agent	agent	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
time	NN	time	time	time	N	O
to	TO	to	to	to	N	O
onset	VB	onset	onset	onset	N	O
of	IN	of	of	of	N	O
cardiomyopathy	NN	cardiomyopathy	cardiomyopathy	cardiomyopathi	Y	B-AdverseReaction
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
was	VBD	was	wa	wa	N	O
86	CD	86	86	86	N	O
days	NNS	days	day	day	N	O
(	(	(	(	(	N	O
range	NN	range	range	rang	N	O
:	:	:	:	:	N	O
27	CD	27	27	27	N	O
to	TO	to	to	to	N	O
253	CD	253	253	253	N	O
days	NNS	days	day	day	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Cardiomyopathy	NNP	cardiomyopathy	cardiomyopathy	cardiomyopathi	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
identified	VBN	identified	identified	identifi	N	O
within	IN	within	within	within	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
month	NN	month	month	month	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
in	IN	in	in	in	N	O
two	CD	two	two	two	N	O
of	IN	of	of	of	N	O
five	CD	five	five	five	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Development	NNP	development	development	develop	N	O
of	IN	of	of	of	N	O
cardiomyopathy	NN	cardiomyopathy	cardiomyopathy	cardiomyopathi	Y	B-AdverseReaction
resolved	VBN	resolved	resolved	resolv	N	O
in	IN	in	in	in	N	O
all	DT	all	all	all	N	O
five	CD	five	five	five	N	O
patients	NNS	patients	patient	patient	N	O
following	VBG	following	following	follow	N	O
dose	JJ	dose	dose	dose	N	O
reduction	NN	reduction	reduction	reduct	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
55	CD	55	55	55	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
dose	VB	dose	dose	dose	N	O
interruption	NN	interruption	interruption	interrupt	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
55	CD	55	55	55	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Across	IN	across	across	across	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
administered	VBD	administered	administered	administ	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
202	CD	202	202	202	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
8%	CD	8%	8%	8%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
developed	JJ	developed	developed	develop	N	O
evidence	NN	evidence	evidence	evid	N	O
of	IN	of	of	of	N	O
cardiomyopathy	NN	cardiomyopathy	cardiomyopathy	cardiomyopathi	Y	B-AdverseReaction
(	(	(	(	(	N	O
decrease	NN	decrease	decrease	decreas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
LVEF	NNP	lvef	lvef	lvef	N	I-AdverseReaction
below	IN	below	below	below	N	O
institutional	JJ	institutional	institutional	institut	N	B-Severity
lower	JJR	lower	lower	lower	N	I-Severity
limits	NNS	limits	limit	limit	N	I-Severity
of	IN	of	of	of	N	I-Severity
normal	JJ	normal	normal	normal	N	I-Severity
with	IN	with	with	with	N	O
an	DT	an	an	an	N	O
absolute	JJ	absolute	absolute	absolut	N	B-AdverseReaction
decrease	NN	decrease	decrease	decreas	N	I-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
LVEF	NNP	lvef	lvef	lvef	N	I-AdverseReaction
10%	CD	10%	10%	10%	N	B-Severity
below	IN	below	below	below	N	I-Severity
baseline	NN	baseline	baseline	baselin	N	I-Severity
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Two	CD	two	two	two	N	O
percent	NN	percent	percent	percent	N	O
demonstrated	VBD	demonstrated	demonstrated	demonstr	N	O
a	DT	a	a	a	N	O
decrease	NN	decrease	decrease	decreas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
LVEF	NNP	lvef	lvef	lvef	N	I-AdverseReaction
below	IN	below	below	below	N	O
institutional	JJ	institutional	institutional	institut	N	B-Severity
lower	JJR	lower	lower	lower	N	I-Severity
limits	NNS	limits	limit	limit	N	I-Severity
of	IN	of	of	of	N	I-Severity
normal	JJ	normal	normal	normal	N	I-Severity
with	IN	with	with	with	N	O
an	DT	an	an	an	N	O
absolute	JJ	absolute	absolute	absolut	N	B-AdverseReaction
decrease	NN	decrease	decrease	decreas	N	I-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
LVEF	NNP	lvef	lvef	lvef	N	I-AdverseReaction
of	IN	of	of	of	N	O
20%	CD	20%	20%	20%	N	B-Severity
below	IN	below	below	below	N	I-Severity
baseline	NN	baseline	baseline	baselin	N	I-Severity
.	.	.	.	.	N	O

Assess	NNP	assess	ass	assess	N	O
LVEF	NNP	lvef	lvef	lvef	N	O
by	IN	by	by	by	N	O
echocardiogram	NN	echocardiogram	echocardiogram	echocardiogram	Y	O
or	CC	or	or	or	N	O
multigated	VBN	multigated	multigated	multig	N	O
acquisition	NN	acquisition	acquisition	acquisit	N	O
(	(	(	(	(	N	O
MUGA	NNP	muga	muga	muga	N	O
)	)	)	)	)	N	O
scan	VBD	scan	scan	scan	Y	O
before	IN	before	before	befor	N	O
initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
,	,	,	,	,	N	O
one	CD	one	one	one	N	O
month	NN	month	month	month	N	O
after	IN	after	after	after	N	O
initiation	NN	initiation	initiation	initi	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
then	RB	then	then	then	N	O
at	IN	at	at	at	N	O
2	CD	2	2	2	N	O
-	:	-	-	-	N	O
to	TO	to	to	to	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
month	NN	month	month	month	N	O
intervals	NNS	intervals	interval	interv	N	O
while	IN	while	while	while	N	O
on	IN	on	on	on	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
combination	NN	combination	combination	combin	N	O
.	.	.	.	.	N	O

Withhold	NNP	withhold	withhold	withhold	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
and	CC	and	and	and	N	O
continue	VB	continue	continue	continu	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
at	IN	at	at	at	N	O
the	DT	the	the	the	N	O
same	JJ	same	same	same	N	O
dose	NN	dose	dose	dose	N	O
if	IN	if	if	if	N	O
absolute	JJ	absolute	absolute	absolut	N	O
LVEF	NNP	lvef	lvef	lvef	N	O
value	NN	value	value	valu	N	O
decreases	NNS	decreases	decrease	decreas	N	O
by	IN	by	by	by	N	O
10%	CD	10%	10%	10%	N	O
from	IN	from	from	from	N	O
pretreatment	NN	pretreatment	pretreatment	pretreat	N	O
values	NNS	values	value	valu	N	O
and	CC	and	and	and	N	O
is	VBZ	is	is	is	N	O
less	RBR	less	le	less	N	O
than	IN	than	than	than	N	O
the	DT	the	the	the	N	O
lower	JJR	lower	lower	lower	N	O
limit	NN	limit	limit	limit	N	O
of	IN	of	of	of	N	O
normal	JJ	normal	normal	normal	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
symptomatic	JJ	symptomatic	symptomatic	symptomat	N	O
cardiomyopathy	NN	cardiomyopathy	cardiomyopathy	cardiomyopathi	Y	O
or	CC	or	or	or	N	O
persistent	NN	persistent	persistent	persist	N	O
,	,	,	,	,	N	O
asymptomatic	JJ	asymptomatic	asymptomatic	asymptomat	N	O
LV	NNP	lv	lv	lv	N	O
dysfunction	NN	dysfunction	dysfunction	dysfunct	N	O
that	WDT	that	that	that	N	O
does	VBZ	does	doe	doe	N	O
not	RB	not	not	not	N	O
resolve	VB	resolve	resolve	resolv	N	O
within	IN	within	within	within	N	O
4	CD	4	4	4	N	O
weeks	NNS	weeks	week	week	N	O
,	,	,	,	,	N	O
permanently	RB	permanently	permanently	perman	N	O
discontinue	VBP	discontinue	discontinue	discontinu	N	O
trametinib	NNS	trametinib	trametinib	trametinib	N	O
and	CC	and	and	and	N	O
withhold	JJ	withhold	withhold	withhold	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
.	.	.	.	.	N	O

Resume	NNP	resume	resume	resum	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
at	IN	at	at	at	N	O
the	DT	the	the	the	N	O
same	JJ	same	same	same	N	O
dose	JJ	dose	dose	dose	N	O
level	NN	level	level	level	N	O
upon	IN	upon	upon	upon	N	O
recovery	NN	recovery	recovery	recoveri	N	O
of	IN	of	of	of	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	O
function	NN	function	function	function	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.3	CD	2.3	2.3	2.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.6	CD	5.6	5.6	5.6	N	O
Ocular	JJ	ocular	ocular	ocular	N	O
Toxicities	NNS	toxicities	toxicity	toxic	N	O

Retinal	JJ	retinal	retinal	retin	N	O
Pigment	NNP	pigment	pigment	pigment	N	O
Epithelial	NNP	epithelial	epithelial	epitheli	N	O
Detachment	NNP	detachment	detachment	detach	Y	O
(	(	(	(	(	N	O
RPED	NNP	rped	rped	rped	N	O
)	)	)	)	)	N	O
:	:	:	:	:	N	O

Retinal	JJ	retinal	retinal	retin	N	B-AdverseReaction
pigment	NN	pigment	pigment	pigment	N	I-AdverseReaction
epithelial	JJ	epithelial	epithelial	epitheli	N	I-AdverseReaction
detachments	NNS	detachments	detachment	detach	N	I-AdverseReaction
(	(	(	(	(	N	O
RPED	NNP	rped	rped	rped	N	B-AdverseReaction
)	)	)	)	)	N	O
can	MD	can	can	can	N	B-Factor
occur	VB	occur	occur	occur	N	O
when	WRB	when	when	when	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
is	VBZ	is	is	is	N	O
used	VBN	used	used	use	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
and	CC	and	and	and	N	O
with	IN	with	with	with	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
single	JJ	single	single	singl	N	O
agent	NN	agent	agent	agent	N	O
[	NNP	[	[	[	N	O
refer	NN	refer	refer	refer	N	O
to	TO	to	to	to	N	O
Full	NNP	full	full	full	N	O
Prescribing	NNP	prescribing	prescribing	prescrib	N	O
Information	NNP	information	information	inform	N	O
for	IN	for	for	for	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Retinal	JJ	retinal	retinal	retin	N	B-AdverseReaction
detachments	NNS	detachments	detachment	detach	N	I-AdverseReaction
resulting	VBG	resulting	resulting	result	N	O
from	IN	from	from	from	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
are	VBP	are	are	are	N	O
often	RB	often	often	often	N	O
bilateral	JJ	bilateral	bilateral	bilater	N	O
and	CC	and	and	and	N	O
multifocal	JJ	multifocal	multifocal	multifoc	N	O
,	,	,	,	,	N	O
occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
macular	JJ	macular	macular	macular	N	O
region	NN	region	region	region	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
retina	NN	retina	retina	retina	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
Trial	NNP	trial	trial	trial	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
ophthalmologic	JJ	ophthalmologic	ophthalmologic	ophthalmolog	N	O
examinations	NNS	examinations	examination	examin	N	O
including	VBG	including	including	includ	N	O
retinal	JJ	retinal	retinal	retin	N	O
evaluation	NN	evaluation	evaluation	evalu	N	O
were	VBD	were	were	were	N	O
performed	VBN	performed	performed	perform	N	O
pretreatment	NN	pretreatment	pretreatment	pretreat	N	O
and	CC	and	and	and	N	O
at	IN	at	at	at	N	O
regular	JJ	regular	regular	regular	N	O
intervals	NNS	intervals	interval	interv	N	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

RPED	NNP	rped	rped	rped	N	B-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
2%	CD	2%	2%	2%	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
55	CD	55	55	55	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
.	.	.	.	.	N	O

Across	IN	across	across	across	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
administered	VBD	administered	administered	administ	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
202	CD	202	202	202	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
RPED	NNP	rped	rped	rped	N	B-AdverseReaction
was	VBD	was	wa	wa	N	O
1%	CD	1%	1%	1%	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
202	CD	202	202	202	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Perform	NNP	perform	perform	perform	N	O
ophthalmological	JJ	ophthalmological	ophthalmological	ophthalmolog	N	O
evaluation	NN	evaluation	evaluation	evalu	N	O
at	IN	at	at	at	N	O
any	DT	any	any	ani	N	O
time	NN	time	time	time	N	O
a	DT	a	a	a	N	O
patient	NN	patient	patient	patient	N	O
reports	NNS	reports	report	report	N	O
visual	JJ	visual	visual	visual	N	O
disturbances	NNS	disturbances	disturbance	disturb	N	O
and	CC	and	and	and	N	O
compare	NN	compare	compare	compar	N	O
with	IN	with	with	with	N	O
baseline	NN	baseline	baseline	baselin	N	O
,	,	,	,	,	N	O
if	IN	if	if	if	N	O
available	JJ	available	available	avail	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
is	VBZ	is	is	is	N	O
used	VBN	used	used	use	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
,	,	,	,	,	N	O
do	VBP	do	do	do	N	O
not	RB	not	not	not	N	O
modify	VB	modify	modify	modifi	N	O
the	DT	the	the	the	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
.	.	.	.	.	N	O

Withhold	NNP	withhold	withhold	withhold	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
if	IN	if	if	if	N	O
RPED	NNP	rped	rped	rped	N	O
is	VBZ	is	is	is	N	O
diagnosed	VBN	diagnosed	diagnosed	diagnos	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
resolution	NN	resolution	resolution	resolut	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
RPED	NNP	rped	rped	rped	N	O
is	VBZ	is	is	is	N	O
documented	VBN	documented	documented	document	N	O
on	IN	on	on	on	N	O
repeat	NN	repeat	repeat	repeat	N	O
ophthalmological	JJ	ophthalmological	ophthalmological	ophthalmolog	N	O
evaluation	NN	evaluation	evaluation	evalu	N	O
within	IN	within	within	within	N	O
3	CD	3	3	3	N	O
weeks	NNS	weeks	week	week	N	O
,	,	,	,	,	N	O
resume	VB	resume	resume	resum	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
lower	JJR	lower	lower	lower	N	O
dose	JJ	dose	dose	dose	N	O
level	NN	level	level	level	N	O
.	.	.	.	.	N	O

Discontinue	NNP	discontinue	discontinue	discontinu	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
if	IN	if	if	if	N	O
no	DT	no	no	no	N	O
improvement	NN	improvement	improvement	improv	N	O
after	IN	after	after	after	N	O
3	CD	3	3	3	N	O
weeks	NNS	weeks	week	week	N	O
[	JJ	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.3	CD	2.3	2.3	2.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Uveitis	NN	uveitis	uveitis	uveiti	Y	O
and	CC	and	and	and	N	O
Iritis	NN	iritis	iritis	iriti	Y	O
:	:	:	:	:	N	O

Uveitis	NN	uveitis	uveitis	uveiti	Y	B-AdverseReaction
and	CC	and	and	and	N	O
iritis	NN	iritis	iritis	iriti	Y	B-AdverseReaction
can	MD	can	can	can	N	B-Factor
occur	VB	occur	occur	occur	N	O
when	WRB	when	when	when	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
is	VBZ	is	is	is	N	O
administered	VBN	administered	administered	administ	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
single	JJ	single	single	singl	N	O
agent	NN	agent	agent	agent	N	O
or	CC	or	or	or	N	O
when	WRB	when	when	when	N	O
used	VBN	used	used	use	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
.	.	.	.	.	N	O

Uveitis	NN	uveitis	uveitis	uveiti	Y	B-AdverseReaction
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
iritis	NN	iritis	iritis	iriti	Y	B-AdverseReaction
)	)	)	)	)	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
1%	CD	1%	1%	1%	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
586	CD	586	586	586	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
single	JJ	single	single	singl	N	O
agent	NN	agent	agent	agent	N	O
and	CC	and	and	and	N	O
uveitis	NN	uveitis	uveitis	uveiti	Y	B-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
1%	CD	1%	1%	1%	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
202	CD	202	202	202	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
.	.	.	.	.	N	O

Symptomatic	JJ	symptomatic	symptomatic	symptomat	N	O
treatment	NN	treatment	treatment	treatment	N	O
employed	VBN	employed	employed	employ	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
included	VBD	included	included	includ	N	O
steroid	NN	steroid	steroid	steroid	N	O
and	CC	and	and	and	N	O
mydriatic	JJ	mydriatic	mydriatic	mydriat	N	O
ophthalmic	JJ	ophthalmic	ophthalmic	ophthalm	N	O
drops	NNS	drops	drop	drop	N	O
.	.	.	.	.	N	O

Monitor	NN	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
for	IN	for	for	for	N	O
visual	JJ	visual	visual	visual	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
uveitis	NN	uveitis	uveitis	uveiti	Y	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
change	NN	change	change	chang	N	O
in	IN	in	in	in	N	O
vision	NN	vision	vision	vision	N	O
,	,	,	,	,	N	O
photophobia	NN	photophobia	photophobia	photophobia	Y	O
,	,	,	,	,	N	O
eye	NN	eye	eye	eye	N	O
pain	NN	pain	pain	pain	Y	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
diagnosed	VBN	diagnosed	diagnosed	diagnos	N	O
,	,	,	,	,	N	O
withhold	JJ	withhold	withhold	withhold	N	O
TAFINLAR	NN	tafinlar	tafinlar	tafinlar	N	O
for	IN	for	for	for	N	O
up	IN	up	up	up	N	O
to	TO	to	to	to	N	O
6	CD	6	6	6	N	O
weeks	NNS	weeks	week	week	N	O
until	IN	until	until	until	N	O
uveitis	JJ	uveitis	uveitis	uveiti	Y	O
iritis	NN	iritis	iritis	iriti	Y	O
resolves	NNS	resolves	resolve	resolv	N	O
to	TO	to	to	to	N	O
Grade	VB	grade	grade	grade	N	O
0	CD	0	0	0	N	O
-	:	-	-	-	N	O
1	CD	1	1	1	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
is	VBZ	is	is	is	N	O
used	VBN	used	used	use	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
,	,	,	,	,	N	O
do	VBP	do	do	do	N	O
not	RB	not	not	not	N	O
modify	VB	modify	modify	modifi	N	O
the	DT	the	the	the	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
.	.	.	.	.	N	O

5.7	CD	5.7	5.7	5.7	N	O
Serious	JJ	serious	serious	seriou	N	O
Febrile	NNP	febrile	febrile	febril	N	O
Reactions	NNS	reactions	reaction	reaction	N	O

Serious	JJ	serious	serious	seriou	N	B-Severity
febrile	JJ	febrile	febrile	febril	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
and	CC	and	and	and	N	O
fever	NN	fever	fever	fever	Y	B-AdverseReaction
of	IN	of	of	of	N	O
any	DT	any	any	ani	N	O
severity	NN	severity	severity	sever	N	O
complicated	VBN	complicated	complicated	complic	N	O
by	IN	by	by	by	N	O
hypotension	NN	hypotension	hypotension	hypotens	Y	B-AdverseReaction
,	,	,	,	,	N	O
rigors	NNS	rigors	rigor	rigor	Y	B-AdverseReaction
or	CC	or	or	or	N	O
chills	NNS	chills	chill	chill	Y	B-AdverseReaction
,	,	,	,	,	N	O
dehydration	NN	dehydration	dehydration	dehydr	Y	B-AdverseReaction
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
renal	JJ	renal	renal	renal	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
,	,	,	,	,	N	O
can	MD	can	can	can	N	B-Factor
occur	VB	occur	occur	occur	N	O
when	WRB	when	when	when	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
is	VBZ	is	is	is	N	O
administered	VBN	administered	administered	administ	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
single	JJ	single	single	singl	N	O
agent	NN	agent	agent	agent	N	O
or	CC	or	or	or	N	O
when	WRB	when	when	when	N	O
used	VBN	used	used	use	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
and	CC	and	and	and	N	O
severity	NN	severity	severity	sever	N	O
of	IN	of	of	of	N	O
pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
are	VBP	are	are	are	N	O
increased	VBN	increased	increased	increas	N	O
when	WRB	when	when	when	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
is	VBZ	is	is	is	N	O
used	VBN	used	used	use	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NNS	trametinib	trametinib	trametinib	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
single	JJ	single	single	singl	N	O
agent	NN	agent	agent	agent	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
Trial	NNP	trial	trial	trial	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
fever	NN	fever	fever	fever	Y	B-AdverseReaction
(	(	(	(	(	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
and	CC	and	and	and	N	O
non	JJ	non	non	non	N	O
-	:	-	-	-	N	O
serious	JJ	serious	serious	seriou	N	O
)	)	)	)	)	N	O
was	VBD	was	wa	wa	N	O
28%	CD	28%	28%	28%	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
and	CC	and	and	and	N	O
10%	CD	10%	10%	10%	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
dacarbazine	NN	dacarbazine	dacarbazine	dacarbazin	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
time	NN	time	time	time	N	O
to	TO	to	to	to	N	O
initial	JJ	initial	initial	initi	N	O
onset	NN	onset	onset	onset	N	O
of	IN	of	of	of	N	O
fever	NN	fever	fever	fever	Y	B-AdverseReaction
(	(	(	(	(	N	O
any	DT	any	any	ani	N	O
severity	NN	severity	severity	sever	N	O
)	)	)	)	)	N	O
was	VBD	was	wa	wa	N	O
11	CD	11	11	11	N	O
days	NNS	days	day	day	N	O
(	(	(	(	(	N	O
range	NN	range	range	rang	N	O
:	:	:	:	:	N	O
1	CD	1	1	1	N	O
to	TO	to	to	to	N	O
202	CD	202	202	202	N	O
days	NNS	days	day	day	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
fever	NN	fever	fever	fever	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
3	CD	3	3	3	N	O
days	NNS	days	day	day	N	O
(	(	(	(	(	N	O
range	NN	range	range	rang	N	O
:	:	:	:	:	N	O
1	CD	1	1	1	N	O
to	TO	to	to	to	N	O
129	CD	129	129	129	N	O
days	NNS	days	day	day	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Serious	JJ	serious	serious	seriou	N	B-Severity
febrile	JJ	febrile	febrile	febril	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
and	CC	and	and	and	N	O
fever	NN	fever	fever	fever	Y	B-AdverseReaction
of	IN	of	of	of	N	O
any	DT	any	any	ani	N	O
severity	NN	severity	severity	sever	N	O
complicated	VBN	complicated	complicated	complic	N	O
by	IN	by	by	by	N	O
hypotension	NN	hypotension	hypotension	hypotens	Y	B-AdverseReaction
,	,	,	,	,	N	O
rigors	NNS	rigors	rigor	rigor	Y	B-AdverseReaction
or	CC	or	or	or	N	O
chills	NNS	chills	chill	chill	Y	B-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
3.7%	CD	3.7%	3.7%	3.7%	N	O
(	(	(	(	(	N	O
7	CD	7	7	7	N	O
187	CD	187	187	187	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
none	NN	none	none	none	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
59	CD	59	59	59	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
dacarbazine	NN	dacarbazine	dacarbazine	dacarbazin	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
Trial	NNP	trial	trial	trial	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
fever	NN	fever	fever	fever	Y	B-AdverseReaction
(	(	(	(	(	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
and	CC	and	and	and	N	O
non	JJ	non	non	non	N	O
-	:	-	-	-	N	O
serious	JJ	serious	serious	seriou	N	O
)	)	)	)	)	N	O
was	VBD	was	wa	wa	N	O
71%	CD	71%	71%	71%	N	O
(	(	(	(	(	N	O
39	CD	39	39	39	N	O
55	CD	55	55	55	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
and	CC	and	and	and	N	O
26%	CD	26%	26%	26%	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
53	CD	53	53	53	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
single	JJ	single	single	singl	N	O
agent	NN	agent	agent	agent	N	O
.	.	.	.	.	N	O

Serious	JJ	serious	serious	seriou	N	B-Severity
febrile	JJ	febrile	febrile	febril	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
and	CC	and	and	and	N	O
fever	NN	fever	fever	fever	Y	B-AdverseReaction
of	IN	of	of	of	N	O
any	DT	any	any	ani	N	O
severity	NN	severity	severity	sever	N	O
complicated	VBN	complicated	complicated	complic	N	O
by	IN	by	by	by	N	O
hypotension	NN	hypotension	hypotension	hypotens	Y	B-AdverseReaction
,	,	,	,	,	N	O
rigors	NNS	rigors	rigor	rigor	Y	B-AdverseReaction
or	CC	or	or	or	N	O
chills	NNS	chills	chill	chill	Y	B-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
25%	CD	25%	25%	25%	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
55	CD	55	55	55	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NNS	trametinib	trametinib	trametinib	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
2%	CD	2%	2%	2%	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
53	CD	53	53	53	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
single	JJ	single	single	singl	N	O
agent	NN	agent	agent	agent	N	O
.	.	.	.	.	N	O

Fever	NNP	fever	fever	fever	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
complicated	VBN	complicated	complicated	complic	N	O
with	IN	with	with	with	N	O
chills	NNS	chills	chill	chill	Y	B-AdverseReaction
rigors	NNS	rigors	rigor	rigor	Y	B-AdverseReaction
in	IN	in	in	in	N	O
51%	CD	51%	51%	51%	N	O
(	(	(	(	(	N	O
28	CD	28	28	28	N	O
55	CD	55	55	55	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
dehydration	NN	dehydration	dehydration	dehydr	Y	B-AdverseReaction
in	IN	in	in	in	N	O
9%	CD	9%	9%	9%	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
55	CD	55	55	55	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
renal	JJ	renal	renal	renal	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
in	IN	in	in	in	N	O
4%	CD	4%	4%	4%	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
55	CD	55	55	55	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
syncope	NN	syncope	syncope	syncop	Y	B-AdverseReaction
in	IN	in	in	in	N	O
4%	CD	4%	4%	4%	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
55	CD	55	55	55	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
Trial	JJ	trial	trial	trial	N	O
2	CD	2	2	2	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
time	NN	time	time	time	N	O
to	TO	to	to	to	N	O
initial	JJ	initial	initial	initi	N	O
onset	NN	onset	onset	onset	N	O
of	IN	of	of	of	N	O
fever	NN	fever	fever	fever	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
30	CD	30	30	30	N	O
days	NNS	days	day	day	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
19	CD	19	19	19	N	O
days	NNS	days	day	day	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
single	JJ	single	single	singl	N	O
agent	NN	agent	agent	agent	N	O
;	:	;	;	;	N	O
the	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
fever	NN	fever	fever	fever	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
6	CD	6	6	6	N	O
days	NNS	days	day	day	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
combination	NN	combination	combination	combin	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
4	CD	4	4	4	N	O
days	NNS	days	day	day	N	O
with	IN	with	with	with	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
single	JJ	single	single	singl	N	O
agent	NN	agent	agent	agent	N	O
.	.	.	.	.	N	O

Across	IN	across	across	across	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
administered	VBD	administered	administered	administ	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
202	CD	202	202	202	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
57%	CD	57%	57%	57%	N	O
(	(	(	(	(	N	O
116	CD	116	116	116	N	O
202	CD	202	202	202	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Withhold	NNP	withhold	withhold	withhold	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
for	IN	for	for	for	N	O
fever	NN	fever	fever	fever	Y	O
of	IN	of	of	of	N	O
101.3	CD	101.3	101.3	101.3	N	O
oF	NN	of	of	of	N	O
or	CC	or	or	or	N	O
higher	JJR	higher	higher	higher	N	O
.	.	.	.	.	N	O

Withhold	NNP	withhold	withhold	withhold	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
for	IN	for	for	for	N	O
any	DT	any	any	ani	N	O
fever	NN	fever	fever	fever	Y	O
higher	JJR	higher	higher	higher	N	O
than	IN	than	than	than	N	O
104	CD	104	104	104	N	O
oF	NN	of	of	of	N	O
.	.	.	.	.	N	O

Withhold	NNP	withhold	withhold	withhold	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
if	IN	if	if	if	N	O
used	VBN	used	used	use	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
,	,	,	,	,	N	O
for	IN	for	for	for	N	O
any	DT	any	any	ani	N	O
serious	JJ	serious	serious	seriou	N	O
febrile	JJ	febrile	febrile	febril	N	O
reaction	NN	reaction	reaction	reaction	N	O
or	CC	or	or	or	N	O
fever	NN	fever	fever	fever	Y	O
complicated	VBN	complicated	complicated	complic	N	O
by	IN	by	by	by	N	O
hypotension	NN	hypotension	hypotension	hypotens	Y	O
,	,	,	,	,	N	O
rigors	NNS	rigors	rigor	rigor	Y	O
or	CC	or	or	or	N	O
chills	NNS	chills	chill	chill	Y	O
,	,	,	,	,	N	O
dehydration	NN	dehydration	dehydration	dehydr	Y	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
renal	JJ	renal	renal	renal	N	O
failure	NN	failure	failure	failur	N	O
and	CC	and	and	and	N	O
evaluate	NN	evaluate	evaluate	evalu	N	O
for	IN	for	for	for	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
infection	NN	infection	infection	infect	Y	O
.	.	.	.	.	N	O

Refer	NN	refer	refer	refer	N	O
to	TO	to	to	to	N	O
Table	VB	table	table	tabl	N	O
2	CD	2	2	2	N	O
for	IN	for	for	for	N	O
recommended	VBN	recommended	recommended	recommend	N	O
dose	NN	dose	dose	dose	N	O
modifications	NNS	modifications	modification	modif	N	O
for	IN	for	for	for	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.3	CD	2.3	2.3	2.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Prophylaxis	NN	prophylaxis	prophylaxis	prophylaxi	Y	O
with	IN	with	with	with	N	O
antipyretics	NNS	antipyretics	antipyretic	antipyret	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
required	VBN	required	required	requir	N	O
when	WRB	when	when	when	N	O
resuming	VBG	resuming	resuming	resum	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
or	CC	or	or	or	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
.	.	.	.	.	N	O

5.8	CD	5.8	5.8	5.8	N	O
Serious	JJ	serious	serious	seriou	N	O
Skin	NNP	skin	skin	skin	N	O
Toxicity	NN	toxicity	toxicity	toxic	N	O

Serious	JJ	serious	serious	seriou	N	B-Severity
skin	NN	skin	skin	skin	N	B-AdverseReaction
toxicity	NN	toxicity	toxicity	toxic	N	I-AdverseReaction
can	MD	can	can	can	N	B-Factor
occur	VB	occur	occur	occur	N	O
when	WRB	when	when	when	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
is	VBZ	is	is	is	N	O
used	VBN	used	used	use	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
and	CC	and	and	and	N	O
with	IN	with	with	with	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
single	JJ	single	single	singl	N	O
agent	NN	agent	agent	agent	N	O
[	NNP	[	[	[	N	O
refer	NN	refer	refer	refer	N	O
to	TO	to	to	to	N	O
Full	NNP	full	full	full	N	O
Prescribing	NNP	prescribing	prescribing	prescrib	N	O
Information	NNP	information	information	inform	N	O
for	IN	for	for	for	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
Trial	NNP	trial	trial	trial	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
any	DT	any	any	ani	N	O
skin	JJ	skin	skin	skin	N	B-AdverseReaction
toxicity	NN	toxicity	toxicity	toxic	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
similar	JJ	similar	similar	similar	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
(	(	(	(	(	N	O
65%	CD	65%	65%	65%	N	O
[	RB	[	[	[	N	O
36	CD	36	36	36	N	O
55	CD	55	55	55	N	O
])	NNS	])	])	])	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
single	JJ	single	single	singl	N	O
agent	NN	agent	agent	agent	N	O
(	(	(	(	(	N	O
68%	CD	68%	68%	68%	N	O
[	RB	[	[	[	N	O
36	CD	36	36	36	N	O
53	CD	53	53	53	N	O
])	NN	])	])	])	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
time	NN	time	time	time	N	O
to	TO	to	to	to	N	O
onset	VB	onset	onset	onset	N	O
of	IN	of	of	of	N	O
skin	JJ	skin	skin	skin	N	B-AdverseReaction
toxicity	NN	toxicity	toxicity	toxic	N	I-AdverseReaction
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
was	VBD	was	wa	wa	N	O
37	CD	37	37	37	N	O
days	NNS	days	day	day	N	O
(	(	(	(	(	N	O
range	NN	range	range	rang	N	O
:	:	:	:	:	N	O
1	CD	1	1	1	N	O
to	TO	to	to	to	N	O
225	CD	225	225	225	N	O
days	NNS	days	day	day	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
median	JJ	median	median	median	N	O
time	NN	time	time	time	N	O
to	TO	to	to	to	N	O
resolution	NN	resolution	resolution	resolut	N	O
of	IN	of	of	of	N	O
skin	JJ	skin	skin	skin	N	B-AdverseReaction
toxicity	NN	toxicity	toxicity	toxic	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
33	CD	33	33	33	N	O
days	NNS	days	day	day	N	O
(	(	(	(	(	N	O
range	NN	range	range	rang	N	O
:	:	:	:	:	N	O
3	CD	3	3	3	N	O
to	TO	to	to	to	N	O
421	CD	421	421	421	N	O
days	NNS	days	day	day	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

No	DT	no	no	no	N	O
patient	NN	patient	patient	patient	N	O
required	VBN	required	required	requir	N	O
dose	JJ	dose	dose	dose	N	O
reduction	NN	reduction	reduction	reduct	N	O
or	CC	or	or	or	N	O
permanent	JJ	permanent	permanent	perman	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
or	CC	or	or	or	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
for	IN	for	for	for	N	O
skin	JJ	skin	skin	skin	N	O
toxicity	NN	toxicity	toxicity	toxic	N	O
.	.	.	.	.	N	O

Across	IN	across	across	across	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
202	CD	202	202	202	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
severe	JJ	severe	severe	sever	N	B-Severity
skin	NN	skin	skin	skin	N	B-AdverseReaction
toxicity	NN	toxicity	toxicity	toxic	N	I-AdverseReaction
and	CC	and	and	and	N	O
secondary	JJ	secondary	secondary	secondari	N	B-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
skin	NN	skin	skin	skin	N	I-AdverseReaction
requiring	VBG	requiring	requiring	requir	N	O
hospitalization	NN	hospitalization	hospitalization	hospit	Y	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
2.5%	CD	2.5%	2.5%	2.5%	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
202	CD	202	202	202	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
.	.	.	.	.	N	O

Withhold	NNP	withhold	withhold	withhold	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
if	IN	if	if	if	N	O
used	VBN	used	used	use	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
,	,	,	,	,	N	O
for	IN	for	for	for	N	O
intolerable	JJ	intolerable	intolerable	intoler	N	O
or	CC	or	or	or	N	O
severe	JJ	severe	severe	sever	N	O
skin	JJ	skin	skin	skin	N	O
toxicity	NN	toxicity	toxicity	toxic	N	O
.	.	.	.	.	N	O

TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
and	CC	and	and	and	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
resumed	VBN	resumed	resumed	resum	N	O
at	IN	at	at	at	N	O
lower	JJR	lower	lower	lower	N	O
dose	NN	dose	dose	dose	N	O
levels	NNS	levels	level	level	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
improvement	NN	improvement	improvement	improv	N	O
or	CC	or	or	or	N	O
recovery	NN	recovery	recovery	recoveri	N	O
from	IN	from	from	from	N	O
skin	JJ	skin	skin	skin	N	O
toxicity	NN	toxicity	toxicity	toxic	N	O
within	IN	within	within	within	N	O
3	CD	3	3	3	N	O
weeks	NNS	weeks	week	week	N	O
[	JJ	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.3	CD	2.3	2.3	2.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.9	CD	5.9	5.9	5.9	N	O
Hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	O

Hyperglycemia	NNP	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction
can	MD	can	can	can	N	B-Factor
occur	VB	occur	occur	occur	N	O
when	WRB	when	when	when	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
is	VBZ	is	is	is	N	O
administered	VBN	administered	administered	administ	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
single	JJ	single	single	singl	N	O
agent	NN	agent	agent	agent	N	O
or	CC	or	or	or	N	O
when	WRB	when	when	when	N	O
used	VBN	used	used	use	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
Trial	NNP	trial	trial	trial	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
5	CD	5	5	5	N	O
of	IN	of	of	of	N	O
12	CD	12	12	12	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
diabetes	NNS	diabetes	diabetes	diabet	Y	O
required	VBN	required	required	requir	N	O
more	RBR	more	more	more	N	O
intensive	JJ	intensive	intensive	intens	N	O
hypoglycemic	JJ	hypoglycemic	hypoglycemic	hypoglycem	N	O
therapy	NN	therapy	therapy	therapi	N	O
while	IN	while	while	while	N	O
taking	VBG	taking	taking	take	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
values	NNS	values	value	valu	N	O
was	VBD	was	wa	wa	N	O
6%	CD	6%	6%	6%	N	O
(	(	(	(	(	N	O
12	CD	12	12	12	N	O
187	CD	187	187	187	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
none	NN	none	none	none	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
dacarbazine	NN	dacarbazine	dacarbazine	dacarbazin	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
Trial	NNP	trial	trial	trial	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
values	NNS	values	value	valu	N	O
was	VBD	was	wa	wa	N	O
5%	CD	5%	5%	5%	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
55	CD	55	55	55	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NNS	trametinib	trametinib	trametinib	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
2%	CD	2%	2%	2%	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
53	CD	53	53	53	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
single	JJ	single	single	singl	N	O
agent	NN	agent	agent	agent	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
serum	VBD	serum	serum	serum	N	O
glucose	JJ	glucose	glucose	glucos	Y	O
levels	NNS	levels	level	level	N	O
as	IN	as	a	as	N	O
clinically	RB	clinically	clinically	clinic	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
when	WRB	when	when	when	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
is	VBZ	is	is	is	N	O
administered	VBN	administered	administered	administ	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
single	JJ	single	single	singl	N	O
agent	NN	agent	agent	agent	N	O
or	CC	or	or	or	N	O
when	WRB	when	when	when	N	O
used	VBN	used	used	use	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
pre	JJ	pre	pre	pre	N	O
-	:	-	-	-	N	O
existing	VBG	existing	existing	exist	N	O
diabetes	NNS	diabetes	diabetes	diabet	Y	O
or	CC	or	or	or	N	O
hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	O
.	.	.	.	.	N	O

Advise	NN	advise	advise	advis	N	O
patients	NNS	patients	patient	patient	N	O
to	TO	to	to	to	N	O
report	VB	report	report	report	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
severe	JJ	severe	severe	sever	N	O
hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
excessive	JJ	excessive	excessive	excess	N	O
thirst	NN	thirst	thirst	thirst	Y	O
or	CC	or	or	or	N	O
any	DT	any	any	ani	N	O
increase	NN	increase	increase	increas	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
volume	NN	volume	volume	volum	N	O
or	CC	or	or	or	N	O
frequency	NN	frequency	frequency	frequenc	N	O
of	IN	of	of	of	N	O
urination	NN	urination	urination	urin	N	O
.	.	.	.	.	N	O

5.10	CD	5.10	5.10	5.10	N	O
Glucose	NNP	glucose	glucose	glucos	Y	O
-	:	-	-	-	N	O
6	CD	6	6	6	N	O
-	:	-	-	-	N	O
Phosphate	NN	phosphate	phosphate	phosphat	Y	O
Dehydrogenase	NNP	dehydrogenase	dehydrogenase	dehydrogenas	N	O
Deficiency	NNP	deficiency	deficiency	defici	N	O

TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
contains	VBZ	contains	contains	contain	N	O
a	DT	a	a	a	N	O
sulfonamide	JJ	sulfonamide	sulfonamide	sulfonamid	N	O
moiety	NN	moiety	moiety	moieti	N	O
,	,	,	,	,	N	O
confers	VBZ	confers	confers	confer	N	O
a	DT	a	a	a	N	O
potential	JJ	potential	potential	potenti	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
hemolytic	JJ	hemolytic	hemolytic	hemolyt	N	B-AdverseReaction
anemia	NN	anemia	anemia	anemia	Y	I-AdverseReaction
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
glucose	JJ	glucose	glucose	glucos	Y	O
-	:	-	-	-	N	O
6	CD	6	6	6	N	O
-	:	-	-	-	N	O
phosphate	NN	phosphate	phosphate	phosphat	Y	O
dehydrogenase	NN	dehydrogenase	dehydrogenase	dehydrogenas	N	O
(	(	(	(	(	N	O
G6PD	NNP	g6pd	g6pd	g6pd	N	O
)	)	)	)	)	N	O
deficiency	NN	deficiency	deficiency	defici	N	O
.	.	.	.	.	N	O

Closely	RB	closely	closely	close	N	O
observe	JJ	observe	observe	observ	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
G6PD	NNP	g6pd	g6pd	g6pd	N	O
deficiency	NN	deficiency	deficiency	defici	N	O
for	IN	for	for	for	N	O
signs	NNS	signs	sign	sign	N	O
of	IN	of	of	of	N	O
hemolytic	JJ	hemolytic	hemolytic	hemolyt	N	O
anemia	NN	anemia	anemia	anemia	Y	O
.	.	.	.	.	N	O

5.11	CD	5.11	5.11	5.11	N	O
Embryofetal	JJ	embryofetal	embryofetal	embryofet	N	O
Toxicity	NN	toxicity	toxicity	toxic	N	O

Based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
its	PRP$	its	it	it	N	O
mechanism	NN	mechanism	mechanism	mechan	N	O
of	IN	of	of	of	N	O
action	NN	action	action	action	N	O
,	,	,	,	,	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
can	MD	can	can	can	N	B-Factor
cause	VB	cause	cause	caus	N	O
fetal	JJ	fetal	fetal	fetal	N	B-AdverseReaction
harm	NN	harm	harm	harm	N	I-AdverseReaction
when	WRB	when	when	when	N	O
administered	VBN	administered	administered	administ	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
woman	NN	woman	woman	woman	N	O
.	.	.	.	.	N	O

Dabrafenib	NNP	dabrafenib	dabrafenib	dabrafenib	N	O
was	VBD	was	wa	wa	N	O
teratogenic	JJ	teratogenic	teratogenic	teratogen	N	B-AdverseReaction
and	CC	and	and	and	N	O
embryotoxic	NN	embryotoxic	embryotoxic	embryotox	N	B-AdverseReaction
in	IN	in	in	in	N	O
rats	NNS	rats	rat	rat	N	B-Animal
at	IN	at	at	at	N	O
doses	NNS	doses	dos	dose	N	O
three	CD	three	three	three	N	O
times	NNS	times	time	time	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
the	DT	the	the	the	N	O
human	JJ	human	human	human	N	O
exposure	NN	exposure	exposure	exposur	N	O
at	IN	at	at	at	N	O
the	DT	the	the	the	N	O
recommended	JJ	recommended	recommended	recommend	N	O
clinical	JJ	clinical	clinical	clinic	N	O
dose	NN	dose	dose	dose	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
this	DT	this	this	thi	N	O
drug	NN	drug	drug	drug	N	O
is	VBZ	is	is	is	N	O
used	VBN	used	used	use	N	O
during	IN	during	during	dure	N	O
pregnancy	NN	pregnancy	pregnancy	pregnanc	Y	O
or	CC	or	or	or	N	O
if	IN	if	if	if	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
becomes	VBZ	becomes	becomes	becom	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
while	IN	while	while	while	N	O
taking	VBG	taking	taking	take	N	O
this	DT	this	this	thi	N	O
drug	NN	drug	drug	drug	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
apprised	VBN	apprised	apprised	appris	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
potential	JJ	potential	potential	potenti	N	O
hazard	NN	hazard	hazard	hazard	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
fetus	NN	fetus	fetus	fetu	N	O
[	NNP	[	[	[	N	O
see	NN	see	see	see	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Specific	NNP	specific	specific	specif	N	O
Populations	NNP	populations	population	popul	N	O
(	(	(	(	(	N	O
8.1	CD	8.1	8.1	8.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Advise	NNP	advise	advise	advis	N	O
female	JJ	female	female	femal	N	O
patients	NNS	patients	patient	patient	N	O
of	IN	of	of	of	N	O
reproductive	JJ	reproductive	reproductive	reproduct	N	O
potential	NN	potential	potential	potenti	N	O
to	TO	to	to	to	N	O
use	VB	use	use	use	N	O
a	DT	a	a	a	N	O
highly	RB	highly	highly	highli	N	O
effective	JJ	effective	effective	effect	N	O
non	NN	non	non	non	N	O
-	:	-	-	-	N	O
hormonal	JJ	hormonal	hormonal	hormon	N	O
method	NN	method	method	method	N	O
of	IN	of	of	of	N	O
contraception	NN	contraception	contraception	contracept	Y	O
since	IN	since	since	sinc	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
can	MD	can	can	can	N	O
render	VB	render	render	render	N	O
hormonal	JJ	hormonal	hormonal	hormon	N	O
contraceptives	NNS	contraceptives	contraceptive	contracept	N	O
ineffective	JJ	ineffective	ineffective	ineffect	N	O
,	,	,	,	,	N	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
and	CC	and	and	and	N	O
for	IN	for	for	for	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
2	CD	2	2	2	N	O
weeks	NNS	weeks	week	week	N	O
after	IN	after	after	after	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
or	CC	or	or	or	N	O
for	IN	for	for	for	N	O
4	CD	4	4	4	N	O
months	NNS	months	month	month	N	O
after	IN	after	after	after	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
trametinib	NN	trametinib	trametinib	trametinib	N	O
.	.	.	.	.	N	O

Advise	NN	advise	advise	advis	N	O
patients	NNS	patients	patient	patient	N	O
to	TO	to	to	to	N	O
contact	VB	contact	contact	contact	N	O
their	PRP$	their	their	their	N	O
healthcare	NN	healthcare	healthcare	healthcar	N	O
provider	NN	provider	provider	provid	N	O
if	IN	if	if	if	N	O
they	PRP	they	they	they	N	O
become	VBP	become	become	becom	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
if	IN	if	if	if	N	O
pregnancy	NN	pregnancy	pregnancy	pregnanc	Y	O
is	VBZ	is	is	is	N	O
suspected	VBN	suspected	suspected	suspect	N	O
,	,	,	,	,	N	O
while	IN	while	while	while	N	O
taking	VBG	taking	taking	take	N	O
TAFINLAR	NNP	tafinlar	tafinlar	tafinlar	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Drug	NNP	drug	drug	drug	N	O
Interactions	NNP	interactions	interaction	interact	N	O
(	(	(	(	(	N	O
7.2	CD	7.2	7.2	7.2	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Specific	NNP	specific	specific	specif	N	O
Populations	NNP	populations	population	popul	N	O
(	(	(	(	(	N	O
8.6	CD	8.6	8.6	8.6	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

